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INTRODUZIONE 
Con il termine di trombosi si intende l’ostruzione di un vaso  venoso o arterioso. 
Il processo trombotico è alla base dei tre maggiori eventi cardiovascolari: l’ischemia 
miocardica, l’ictus cerebri e il tromboembolismo venoso1.  E’ stato calcolato 
dall’Organizzazione Mondiale della Sanità che nel 2010 circa 7 milioni di morti possono 
essere ricondotte ad una ischemia cardiaca e più di 2 milioni di morti ad una ischemia 
cerebrale2. In Italia l’ictus è la terza causa di morte dopo le malattie cardiovascolari e le 
neoplasie, causa il 0%- 2%  di tutti i decessi per anno e rappresenta la principale causa 
d’invalidità3. Nel 2004 in Europa sono state segnalate più di cinquecentomila morti 
associate a tromboembolismo venoso4. L’incidenza  di trombosi venosa si attesta 
attorno allo 0.75-2.69 per mille persone, e raggiunge la soglia di 2-7 malati ogni 1000 
persone, se si considera una popolazione di più di 70 anni5. 
Classicamente si riconoscono alcuni fattori di rischio per lo sviluppo di trombosi. Sin 
dagli inizi del 1900 è noto che la presenza degli elementi della cosiddetta triade di 
Virchow (ipercoagulabilità, rallentamento del flusso sanguigno e lesione vascolare) 
sono alla base dello sviluppo di trombosi venosa. Vengono considerati fattori di rischio 
trombotico:  l’immobilizzazione, la presenza di malattia  neoplastica,  la chirurgia 
recente, soprattutto ortopedica, o la presenza di predisposizione genetica (trombofilia)6. 
I due meccanismi associati allo sviluppo di uno stato trombofilico sono rappresentati 
dalla ridotta attività dei fattori anticoagulanti e dall’aumentata attività dei fattori 
procoagulanti (per aumentata sintesi, per mancata inattivazione di elementi normali o 
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per la produzione di elementi iperfunzionanti)7. Le condizioni trombofiliche possono 
essere ereditarie come la mutazioni del fattore V di Leiden,  la mutazione G20210 delle 
protrombina, il deficit di proteine C ed S oppure possono essere acquisite come in caso 
dello sviluppo di anticorpi antifosfolipidi; le mutazioni del fattore V o della protrombina 
rappresentano la forma di trombofilia più frequente nella popolazione ( 2-5% 
nell’ambito della razza caucasica) e sono associate ad un aumento del rischio di 
sviluppare trombosi di 2- 5 volte8. 
La chirurgia ortopedica maggiore è associata ad un rischio di trombosi venosa 
maggiore rispetto a tutte le altre specialità chirurgiche; tanto che in questi casi è 
raccomandato l’utilizzo di una profilassi antitrombotica che deve essere portata avanti 
per almeno 35 giorni9. 
Sul versante arterioso l’ipertensione, il diabete, il fumo di sigaretta, la dislipidemia sono 
riconosciuti essere fattori che favoriscono la formazione di placche aterosclerotiche e 
quindi la successiva occlusione vascolare10. 
Recentemente è stata posta l’attenzione sulla necessità di una valutazione del rischio 
cardiovascolare totale, che tenga conto di tutti i fattori di rischio che,quando presenti 
contemporaneamente, possono potenziarsi a vicenda, risultando in un maggior rischio 
rispetto alla somma dei singoli componenti11. La prevalenza complessiva 
dell’ipertensione risulta compresa tra il 30% e 45% nella popolazione generale, con un 
netto incremento con il crescere dell’età e rappresenta la principale causa di ictus. 
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Il fumo di sigaretta rappresenta il principale fattore di rischio modificabile per eventi 
cardiovascolari, esso agisce determinando una disfunzione endoteliale ed un  aumento 
dell’attivazione piastrinica creando un ambiente protrombotico12. 
I pazienti affetti da diabete mellito sono sottoposti ad un rischio 2-3 volte maggiore di 
sviluppare eventi cardiovascolari e gli eventi cardiovascolari rappresentano la 
principale causa di morte per i pazienti diabetici13. 
Nel recente passato si è posta l’attenzione sulla ricerca di nuovi condizioni a rischio, 
per poter giustificare lo sviluppo di trombosi definite “idiopatiche”. Ad esempio ci si è 
chiesti se i classici  fattori di rischio per trombosi arteriosa potessero avere un ruolo 
anche nello sviluppo di trombosi venosa;  sono stati pubblicati quindi studi riguardanti 
l’associazione tra aterosclerosi o sindrome metabolica e la trombosi venosa14. 
Recentemente si  è posta l’attenzione sul ruolo dello stress psicologico come fattore di 
rischio per lo sviluppo di accidenti cerebrovascolari.15 
Inoltre il sesso maschile che è classicamente  associato ad un maggiore rischio di 
trombosi arteriosa,  sembra essere protettivo per lo sviluppo di recidive di trombosi 
venose.16 
Nell’ambito delle nostre osservazioni abbiamo voluto porre l’attenzione su alcune 
condizioni particolari, di frequente riscontro nella popolazione generale, e sulla loro 
possibile correlazione con lo sviluppo di trombosi. In particolare abbiamo analizzato la 
correlazione tra trait talassemico e lo sviluppo di eventi cardiovascolari, abbiamo 
analizzato l’effetto pro coagulante mediato dalla presenza di tireotossicosi e il rischio 
trombotico correlato; è stata inoltre analizzato la terapia anticoagulante ottimale da 
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attuare in corso di una condizione fisiologica come la gravidanza, che si associa ad un 
aumentato rischio di sviluppare tromboembolia; infine ci siamo occupati della terapia 
anticoagulante orale e dell’individuazione di soggetti a maggior rischio di complicanze 
trombotiche o emorragiche perché impossibilitati a mantenere un’adeguata stabilità 
della terapia. 
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OBIETTIVI 
Nell’ambito di questo progetto di dottorato ci si è occupati dell’analisi di nuovi ed 
inusuali fattori di rischio trombotico, della terapia antitrombotica attuata in particolari 
condizioni a rischio e, nell’ultima sezione, della terapia anticoagulante orale al fine di 
individuare i pazienti esposti ad un aumentato rischio trombotico perché geneticamente 
predisposti ad una maggiore instabilità della terapia con i classici anticoagulanti orali. 
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Talassemia 
Le sindromi talassemiche17 rappresentano un gruppo di disordini ereditari caratterizzati 
dall’abolizione o dalla riduzione della sintesi di una o più catene globuliniche, con 
conseguente anemizzazione ed eritropoiesi inefficace.  
La talassemia tipo beta è caratterizzata dalla diminuita o assente sintesi di catene 
beta-globuliniche. Dal punto di vista clinico si distinguono varie forme a seconda della 
gravità: 
- Talassemia maior: forma più grave che esordisce precocemente e 
determina marcata anemia con ittero, epatosplenomegalia e alterazioni ossee 
- Talassemia intermedia: caratterizzata da anemia di grado variabile ad 
esordio più tardivo, senza evidenti alterazioni dello sviluppo psicomotorio ma 
con evidente eritropoiesi extramidollare e possibile sviluppo di calcolosi della 
colecisti 
- Talassemia minor o trait talassemico: condizione asintomatica 
caratterizzata da microcitosi,  e lieve anemia  
In alcuni studi è stata evidenziato un aumentato rischio trombotico in pazienti affetti da 
talassemia intermedia18, mentre risultava meno definito il rischio trombotico in pazienti 
affetti da trait talassemico. 
Abbiamo quindi deciso di condurre una revisione sistematica della letteratura valutando 
l’associazione tra eventi cardiovascolari arteriosi e trait talassemico.  
Utilizzando i motori di ricerca MEDLINE ed EMBASE abbiamo eseguito una ricerca 
utilizzando le parole chiave: Thalassemia, beta-Thalassemia, Acute Coronary 
Syndrome, Myocardial Infarction, Unstable Angina, Stroke, Transient ischemic attack. 
L’identificazione e la selezione degli studi inerenti è stata eseguita indipendentemente 
da due ricercatori. E’ stata analizzata la prevalenza di trait talassemico in paziente 
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affetti da patologia cardio-cerebrovascolare. Inoltre sono state eseguite sottoanalisi 
riguardanti pazienti di sesso maschile.   Nel nostro lavoro sono stati identificati più di 
300 articoli, ma solo 8 , per un totale di più di 3000 casi e 6000 controlli, sono risultati 
eleggibili per l’esecuzione della metanalisi. I nostri risultati hanno evidenziato che il trait 
talassemico sembra essere un fattore protettivo rispetto allo sviluppo di accidenti 
cerebro o cardiovascolare solo nei soggetti di sesso maschile. 
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THALASSEMIA TRAIT AND ARTERIAL THROMBOEMBOLIC EVENTS: A SYSTEMATIC 
REVIEW AND A META-ANALYSIS OF THE LITERATURE19 
F. Dentali, E. Romualdi, W. Ageno, MD Cappellini, PM Mannucci 
 
 Introduction:  
β-thalassemia is a congenital haemolytic anaemia characterized by a deficiency in the production of β-
globin chains [1]. An increased incidence of venous  thromboembolic events has been reported in 
thalassemic patients, especially in patients with β-thalassemia intermedia [2]. A number of prothrombotic 
conditions have been described in this population which support the biological plausibility of this 
observation. These in particular include increased thrombin generation by structurally abnormal red blood 
cells [3], increased platelet activation [4], endothelial inflammation, reduction of protein C and S levels, 
elevated levels of von Willebrand factor, and specific changes in the lipid membrane composition of 
abnormal red blood cells [2]. 
On the other hand, the risk of atherothrombotic complications is well established in β-thalassemia trait 
carriers. β-thalassemia trait carriers usually present with anaemia with low blood viscosity levels, 
secondary to microcytosis [5], and hypolipidaemia  [6]. A number of studies have suggested that because 
of low serum cholesterol levels, chronic anaemia and reduced blood viscosity, these patients may actually 
be protected from atherothrombotic cardiovascular disease [7-9]. On the basis of these observations, we 
performed a systematic review of the literature and a meta-analysis of all studies that compared the 
prevalence of β-thalassemia trait in patients with arterial thromboembolic events or objectively 
documented major atherosclerotic lesions and in healthy controls. 
Methods:  
Studies were identified using the MEDLINE (1950 to July  Week 4 2010) and EMBASE (1980 to July 
Week 4 2010) electronic databases.  The search strategy  was  
developed without any language restriction, and used the following keywords: Thalassemia, beta-
Thalassemia, Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina, Stroke, Transient 
ischemic attack. Research was supplemented by manually reviewing abstract books from the Congress of 
the International Society on Thrombosis and Haemostasis (ISTH), from the Congress of the American 
Society of Haematology (ASH) and the reference lists of all retrieved articles. Case control or cohort 
studies were included if they met the following criteria: i) diagnosis of arterial thromboembolic events 
was objectively confirmed; ii) patients were compared to a control group of healthy subjects without a 
history of thromboembolic disease or genetic relationship with the patients or to subjects with similar 
characteristics of cases; iii). an objective definition of β-thalassemia was provided.  
The following data were extracted: study characteristics (year of publication, design, study centre) and 
patients and controls characteristics (number of subjects studied, mean age, 
variation in age, gender and race). 
Study identification, study selection and data extraction were performed independently in duplicate by 
two reviewers, with disagreements resolved through discussion or by the 
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opinion of a third reviewer, if necessary. The agreement between the reviewers was calculated using the 
kappa (k) statistic [10]. 
  
Review Manager (RevMan; version 4.2 for Windows; Oxford, England; The Cochrane Collaboration, 
2003) was used to pool data for each risk factor. Odds ratios (ORs) and 
95% confidence intervals (CIs) were calculated using a random-effects model [11]. Statistical 
heterogeneity was evaluated using the I2 statistic, which assesses the appropriateness of pooling the 
individual study results [12]. The I2 value provides an estimate of the amount of variance across studies 
due to heterogeneity rather than chance. P < 0,05 was considered to denote statistically significant 
heterogeneity. To further explore potential sources of heterogeneity, studies with different design were 
analyzed separately. 
The proportion of arterial cardiovascular events  in the population that could be attributed to the presence 
of β-thalassemia trait (population attributable risk [PAR]) was estimated as follows: 
PAR = 100 x [Prevalence (OR – 1) / Prevalence (OR – 1)+ 1] 
For this calculation we estimated the prevalence of exposure as the genotype frequency among control 
subjects. 
A subgroup analysis  on studies that included only patients with clinical events was performed. 
Furthermore, another subgroup analysis including only patients with cardiovascular disease was 
performed. Since some studies suggested a different role of β-thalassemia trait in male and female 
[14,15,17,18,21] we performed a subgroup analysis according to gender. 
The presence of publication bias was explored using funnel plots of effect 
size against standard error [13]. 
 
Results:  
A total of 342 (139 Medline and 203 Embase) citations and 12  abstracts from ISTH congresses were 
identified by our systematic search. A total of 325 studies were excluded after reviewing the study 
abstracts. We retrieved the full text of 17 articles, 9 were excluded because they did not meet the 
predefined inclusion and 7 case-control studies and 1 prospective cohort study were eligible for inclusion 
in our systematic review [14-21]. Two studies were from Iran [17,18], two from Greece [19,20], one from 
the US [14], one from Taiwan [21] , one from India [16], and one from Italy [15]. All studies were written 
in English. 
The inter-observer agreement for the study selection was total (k=1.0). 
Five studies enrolled patients with acute myocardial infarction [14-16, 19,21], one enrolled patients with 
acute cerebrovascular ischemic events [18], one enrolled patients with coronary atherosclerosis diagnosed 
angiographically  [17], and one enrolled patients with clinical and electrocardiographic findings 
suggestive for stable angina [20]. It remains unclear if (and how many) patients  enrolled in the last two 
studies had previous concomitant cardiovascular events. Three studies [ 14,19,21] enrolled only male 
patients and controls whereas the other five  [15-18, 20] enrolled male and female patients and controls.  
The prevalence of β-thalassemia trait was evaluated in 3172 patients with cardiovascular or 
cerebrovascular events and in 6307 controls. Baseline characteristics of included studies are summarized 
in table 1. 
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β -thalassemia trait was associated with a reduced risk of developing arterial cardiovascular and 
cerebrovascular events (OR  0.45; 95%  CI 0.45-0.60), Figure 1. Heterogeneity among studies was low 
(I2 = 13 %). 
The funnel plots for arterial cardiovascular and cerebrovascular events appeared symmetric, suggesting 
the absence of publication bias. 
The proportion of arterial cardiovascular  and cerebrovascular events that could be avoided due to the 
presence of β-thalassemia trait in this pooled cohort was 4.4%.   
Subgroup analysis that excluded the two studies that only enrolled patients with coronary atherosclerosis 
diagnosed angiographically and with electrocardiographic findings suggestive for stable angina [17, 20] 
gave similar results (OR  0.45; 95%  CI 0.33-0.63). 
Subgroup analysis that included only studies that enrolled patients with cardiovascular complication gave 
similar results (OR  0.40; 95%  CI 0.30-0.54). 
Five studies [14,15,17,18,21], with a total of 1883 patients and 3583 controls, considered the role of β-
thalassemia trait in male subjects, whereas only 3 studies [15,17,18], with a total of 332 patients and 2236 
controls, considered the role of β-thalassemia trait in female subjects. Subgroups analysis in male subjects 
confirmed the results of the principal analysis (OR 0.39; 95% CI 0.24-0.62), whereas the presence of β-
thalassemia trait did not  appear to affect the risk of arterial cardiovascular and cerebrovascular events in 
female subjects (OR 0.89; 95% CI 0.52-1.53). Figure 2. 
 
Discussion: 
This is the first  systematic review and meta-analysis that assessed the association between β-thalassemia 
trait and arterial cardiovascular and cerebrovascular events. Our results suggest that the presence of β-
thalassemia trait could be protective against arterial thrombotic disorders. This conclusion is strengthened 
by the large number of included cases that exceeded  three thousand patients and by the uniform nature of 
our results. Subgroups analysis in male subjects confirmed the results of the principal analysis. On the 
other hand, the presence of  β-thalassemia trait did not appear to be protective in female subjects.  
Our findings are different from those obtained in previous studies carried out in patients with β-
thalassemia major or intermedia, in which both conditions, and in particular thalassemia intermedia, were 
associated with an increased risk of venous thromboembolic events [2]. Furthermore, recent studies have 
shown a high risk of  symptomatic and asymptomatic brain ischaemia in patients with β-thalassaemia 
intermedia [23,24]. 
This increased risk has been supported by the identification of a number of prothrombotic conditions such 
as the increased thrombin generation due to structurally abnormal red blood cells and increased platelet 
activation, which are likely absent or at least less pronounced in patients with β-thalassemia trait [25]; 
unfortunately there are not specifically designed studies to identify the real incidence of venous 
thrombotic events in β-thalassemia trait carriers. Conversely, the protective role of  β-thalassemia trait 
against arterial cardiovascular or cerebrovascular disease could be explained by a number of different 
mechanisms including a reduction in serum cholesterol levels [6] and in blood viscosity [5,9]. In addition, 
some of the selected studies [15,18] also reported a reduced prevalence of arterial hypertension  in β-
thalassemia trait carriers than in controls suggesting a protective role of this condition. This was recently 
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confirmed in a study performed by Vyssoulis et al in which β-thalassemia trait carriers had a better 24-h 
blood pressure profile in comparison with anemic and non-anemic hypertensives patients [26].  
Interestingly, the protective effect of β-thalassemia trait was considerably stronger in male patients (61% 
risk reduction) than in female patients (11% risk reduction), and in this latter group this effect was not 
statistically significant. This result may be due to truly existing, gender related, protective mechanisms of 
β-thalassemia trait, or simply to the relatively low number of female patients with cardiovascular events 
included in this subgroup analysis.   
Our meta-analysis has limitations. First, it was restricted to case-control  and cohort studies, and the 
application of formal meta-analytic methods to observational studies is controversial, since bias implicit 
in the study design may misrepresent the strength of associations within the data [20]. Second the 
definition of β-thalassemia trait was heterogeneous across studies. However, we only included studies in 
which an objective definition of β-thalassemia trait was reported. Third, since we have no access to the 
raw data of the single studies, it was not possible to perform separate analyses evaluating the association 
between beta-thalassemia trait and cardiovascular events in normotensive and hypertensive patients. Last, 
despite a careful review of references and research in the abstracts books of ISTH and ASH we failed to 
identify any published or unpublished study not found in our initial literature search. Because it is 
recognized that publication bias can affect the results of meta-analyses, we attempted to assess this 
potential bias using a funnel plot. However, funnel plot  appeared symmetric suggesting the absence of 
publication bias. 
In conclusion, the results of this systematic review of the literature and meta-analysis suggest that β-
thalassemia trait may act as a protective factor against the developing of major atherothrombotic lesions 
or acute arterial thromboembolic events. Larger prospective studies are necessary to confirm these 
preliminary findings and to further investigate the mechanisms underlying this protective effect. 
 
 
Figure 1 Association between cardiovascular events and β-thalassemia trait 
 
 
 
 
 
  
Table 1. Baseline characteristics of included studies 
Study  Type  Inclusion End-point Other Results Other Diagnosis  
Hashemi et al. 
Cardiovasc J 2007 
Case-control Pts underwent 
coronary 
angiography 
Association of beta 
thal trait with CAD 
Stepwise multivariate 
regression  to study 
thal mechanism 
CAD+/TT+:16 of 
615 
CAD-/TT+:15 of 
604 
P:n.s. 
Only hematocrit 
was different 
MCV <78, 
MCH<27, 
HbA2>3.5% 
Karimi et al. J of 
Stroke and 
Cardiovasc Dis 
2008 
Case control Pts with acute 
focal neurologic 
deficits; Controls: 
age and sex 
matched 
Presence of beta thal 
trait 
Presence of 
hypertension, 
diabetes, 
hyperlipidemia 
TT+: in 9 of 148 
case and in  19 of 
156 controls  
P:0.066 
In male pt p: 0.008 
Negative 
association 
hypertention and 
TT only in male pt 
MCV <80, 
MCH<27, 
HbA2>3.5% 
Tassiopoulos et al. 
Ann NY Academy 
of Sc 2005 
Case control Pts with stable 
angina pectoris 
with advanced 
CAD or without 
CAD 
Presence of beta thal 
Trait 
Smoke, hypertension, 
diabetes, 
hypercholesterolemia 
aCAD+/TT+: 
16/464 pt  
aCAD-/TT+:  
15/174 pt (8.62%) 
p:0.001 
 Hemoglobin 
electrophoresis 
Tassiopoulos et al. 
Haematol 1995 
Case control Male pts with 
AMI (cases) and 
212 males 
orthopedic pts 
(controls) 
Presence of beta thal 
Trait 
- TT+/AMI+: 9/209;  
TT+/AMI-: 18/212 
 
- Red cells 
morphology, HbA2 
and HbF 
Crowley et al.Acta 
Haematol 1987 
Case control Males with AMI 
(cases), males >24 
years admitted for 
other reasons 
(controls) 
Presence of beta thal 
Trait 
- TT+/AMI+: 2/359; 
TT+/AMI-: 11/330  
P<0.01 
- MCV <80, England 
and Frasier index 
neg 
  
Wang et al Am J 
Haematol 1995 
Case control Males with AMI 
(cases); Males 
without MI 
(controls) 
Presence of beta thal 
Trait 
cholesterol TT+/AMI+: 
14/500; 
TT+/AMI-:33/500 
P<0.01 
Cholesterol was 
significantly lower 
in TT+ 
MCV <80, England 
and Frasier index 
neg 
Gulati er al 
Journ of Intern 
Med of India 
Case control Pts with AMI 
(cases); blood 
donors (controls) 
Presence of beta thal 
Trait 
- TT+/AMI+: 8/430; 
TT+/AMI-:15/377 
P<0.01 
 Clinical and 
laboratory criteria 
Gallerani et al. J 
Intern Med 1991 
Prospective study Pts admitted to 
hospital; no thal 
(cases) and beta 
thal trait (controls) 
Prevalence of 
thromboembolic 
events 
DM, hypertension AMI+/TT+: 
17/447 
AMI+/TT-
:367/3954 
P=n.s. 
P sign only in 
males: 
AMI+/TT+: 7/200 
AMI+/TT: 
275/2243  
DM and 
hypertension were 
significantly lower 
in TT+ 
Abnormal red cell 
morphology, 
decreased osmotic 
red cells fragility , 
HbA2>3 % 
England and Frasier 
index neg 
DM diabetes mellitus; AMI acute myocardial infarction; TT+ trait carriers; coronary artery disease 
 
Figure 2 Association between cardiovascular events and β-thalassemia trait in  male and female patients 
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Distiroidismo 
Si tratta di una condizione caratterizzata da un’alterata concentrazione degli ormoni 
tiroidei nell’organismo;  si parla di tireotossicosi quando sia presente un eccesso di 
ormoni tiroidei nel torrente ematico (sia per produzione endogena sia per assunzione 
incongrua di terapia con levotiroxina).  
In caso patologia della ghiandola tiroidea si definisce ipotiroidismo conclamato la 
situazione caratterizzata da una riduzione dei livelli di tiroxina (T4) ed un aumento dei 
livelli di tireotropina (TSH), al contrario si definisce ipertiroidismo conclamato la 
condizione caratterizzata da un aumento dei valori di T4 con TSH ridotto. 
Il legame tra disfunzione tiroidea e sistema emostatico è stato ipotizzato fin dagli inizi 
del ventesimo secolo. 
In pazienti ipotiroidei è stata osservata una tendenza al sanguinamento, soprattutto 
interessante il distretto muco-cutaneo20. Inoltre pazienti affetti da ipotiroidismo 
conclamato spesso hanno presentato lo sviluppo della malattia di von Willebrand 
acquisita21. 
In corso di ipertiroidismo sono state evidenziate alcune alterazioni del sistema 
emocoagulativo tali da suggerire la presenza di uno stato trombofilico. In particolare è 
stata evidenziata un’aumentata attività del fattore VIII e del fattore IX ed una riduzione 
dell’attività fibrinolitica22; tali alterazioni sono state evidenziate anche in corso di terapia 
ormonale. 
Data la rilevanza clinica abbiamo deciso di condurre una revisione sistematica della 
letteratura e una metanalisi al fine di valutare gli effetti della tireotossicosi sul sistema 
coagulativo e il rischio di tromboembolia venosa.  
                                                 
20
 Ford HC, Carter JM. Haemostasis in hypothyroidism. Postgrad Med J 1990; 66: 280-4 
21
. Stuijvert. J F, Piantanida E, Vanzaane B. et al. Acquired von Willebrand syndrome in patients 
with overt hypothyroidism: a prospective cohort study. Haemophilia  2013: 1–7 
22
 Erem C, Ersoz H, Karti SS et al. Blood coagulation and fibrinolysisin hyperthyroidism. J 
Endocrinol Invest 2002;25:345-50 
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Utilizzando i motori di ricerca MEDLINE ed EMBASE sono stati identificati gli studi tesi 
a valutare l’effetto della tireotossicosi sul sistema emocoagulativo; sono stati esclusi 
case reports, review e studi in vitro.  
Sono stati selezionati più di 1000 articoli, di questi solo 29 sono stati utilizzati 
nell’analisi. 
Con il nostro studio abbiamo osservato che in corso di tireotossicosi si sviluppa un 
evidente stato trombofilico, determinato da un netto aumento di alcuni fattori della 
coagulazione a scapito del decremento di elementi determinati nelle fibrinolisi; 
nonostante ciò resta ancora da definire la vera incidenza di trombosi venosa in tali 
circostanze.  
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THE EFFECT OF HYPERTHYROIDISM ON PROCOAGULANT, ANTICOAGULANT AND 
FIBRINOLYTIC FACTORS 
A SYSTEMATIC REVIEW AND META-ANALYSIS23 
Danka J. F. Stuijver; Bregje van Zaane; Erica Romualdi; Dees P. M. Brandjes; Victor E. A. Gerdes; 
Alessandro Squizzato 
 
Introduction 
Hyperthyroidism is associated with a hypercoagulable state (1, 2). Several coagulation and fibrinolytic 
parameters appear to be affected by thyrotoxicosis; elevated plasma levels of factor VIII (FVIII), factor 
IX (FIX), von Willebrand factor (VWF), and fibrinogen, and a reduced fibrinolytic activity due to 
increased levels of plasminogen activator inhibitor-1 (PAI-1) have been reported in both hyperthyroid 
patients and healthy subjects after taking thyroid hormones (1, 3–9). However, in a previous systematic 
review, we found the majority of these studies to have major methodological flaws (1). This left the net 
effect of thyroid hormone excess on the haemostatic system unclear. Moreover, the question as to 
whether thyrotoxicosis enhances the risk of venous thrombosis, and to which extent, still remains 
controversial. In this review, we aimed to update our previous systematic review and systematically 
summarise and meta-analyse the data by assessing the effects of thyrotoxicosis on the coagulation and 
fibrinolytic system in vivo (1). For the interpretation of the results we will also discuss the recent studies 
on the relationship between (supra) physiological thyroid hormone levels and VTE. 
 
Methods 
Study identification 
A computer-assisted search of the MEDLINE and EMBASE electronic databases from July 2006 to 
March 2012 was performed to identify published studies that evaluated the effect of thyroid hormone 
excess on the coagulation-fibrinolytic system. The following search terms were used for the MEDLINE 
search: “haemostasis, blood coagulation tests, blood coagulation, blood coagulation fac- tors, blood 
coagulation disorders, thyroid diseases, thyroid hormones, thyroid dysfunction, thyroid receptors, thyroid 
hormone, hyperthyroidism”. For the EMBASE database search, the terms “haemostasis, blood clotting, 
blood clotting test, blood clotting factor, blood clotting disorders, thyroid disease, thyroid hormone, 
thyroid hormone receptor, and hyperthyroidism” were used. Reference lists of all included studies were 
manually searched for other potentially eligible studies. All included studies were merged with the studies 
found in our previous search from January 1980 until June 2006 (1). 
Inclusion criteria 
Two investigators (D.S. and B.v.Z) performed the study selection independently. Main inclusion criterion 
was that the study had to evaluate the effect of thyrotoxicosis, overt and/or subclinical, on the 
coagulation-fibrinolytic system in vivo. The following study designs were allowed: 1) observational 
cross-sectional studies in which hyperthyroid individuals were compared to euthyroid controls or 2) 
observational intervention studies in which laboratory tests were performed before and after treatment to 
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correct hyperthyroidism, or 3) experimental clinical trials in which euthyroid subjects received a thyroid 
hormone analogue to induce exogenous thyrotoxicosis. Case reports, case series, reviews, editorials, in 
vitro, and non-human studies were excluded. Moreover, studies on cancer patients (as cancer itself 
influences the coagulation system) and studies without statistical analysis were excluded. No language 
restrictions were initially applied to the search strategy, but only articles written in English, French, 
Spanish, German, Dutch, and Italian were evaluated. The two investigators independently reviewed titles 
and/or abstracts from the initial search to determine whether the inclusion criteria were satisfied. The full 
text of the study was obtained when an article could not be excluded with certainty. Decisions regarding 
inclusion were made separately, results were compared, and any disagreement was resolved by 
discussion. When multiple articles for a single study had been published, it was decided to use the latest 
publication and to supplement it, if necessary, with data from the earlier publications. 
Quality assessment 
The quality of randomised and non-randomised clinical trials was assessed in an extended version of the 
Delphi list (the Maastricht- Amsterdam list) (10, 11). The Newcastle-Ottawa Scale (NOS scale) 
for assessing quality of observational studies was used as a guide to assess study quality of cross-sectional 
and intervention studies (12). For summarising study validity, we adopted a simple Cochrane 
Collaboration approach (13). Three categories were therefore identified: high quality (low risk of bias), 
medium quality (moderate risk of bias), or low quality (high risk of bias). Quality of the included studies 
was assessed independently by the same two reviewers and any differences were resolved by consensus 
or the opinion of the third reviewer, if necessary. No attempts to mask for authorship, journal name or 
institution were made. 
Statistical analysis 
For each outcome and for each study we extracted the effect sizes comparing the exposed and control 
situations. This implies that in cross-sectional studies hyperthyroid patients and controls were compared, 
whereas in intervention studies pre- and post-treatment values were evaluated. In experimental trials, 
post- versus pre-exposure values, or post-intervention versus values without intervention, were compared. 
A positive effect size reflected higher values in the exposed situation (i.e. thyroid hormone excess), 
whereas a negative effect size reflected lower values in the exposed situation. Results were expressed as 
standardised mean difference, i.e. the difference between the group means divided by the pooled standard 
deviation (14). If, instead of standard deviations (SD), standard errors of the mean (SEM) were provided, 
the SD based on the SEM and the number of subjects (SEM = SD / √ n) was calculated. If, instead of SD, 
the 95% confidence interval (CI) was given, the SEM was calculated based on the z-score, the upper limit 
and the mean value (SEM = upper limit-mean/z-score). For those articles that did not report exact 
statistics, we only documented the authors’ statements on the statistical difference per outcome using 
notations of statistical significant increase, statistical significant decrease or no statistical significant 
difference. Data were categorised according to 1) study design and 2) subclinical and overt 
hyperthyroidism (in cross-sectional studies). These data were pooled using a fixed-effects model and 
comparing these findings with the results obtained using a random-effects model, in particular in case of 
significant statistical heterogeneity (15, 16). In case of high statistical heterogeneity, results using 
random- effects model are reported. Statistical heterogeneity was evaluated using the I2 statistic, which 
assesses the appropriateness of pooling the individual study results. The I2 value provides an estimate 
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of the amount of variance across studies due to heterogeneity rather than chance. I2< 30% indicates mild 
heterogeneity, 30–50% moderate, and >50% severe heterogeneity. When heterogeneity was present, we 
repeated the analysis removing one study at time to assess the source of heterogeneity. All statistical 
calculations were performed using Review Manager 5.0 computer software (Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2008). 
 
Results 
Search results and included studies 
 From our previous search from January 1980 to June 2006, a total of 18 articles had been identified (3–6, 
8, 17–29). Our new search identified a further 1,233 citations from the database and reference searches. 
Of these, 96 publications were considered potentially relevant. Forty casereports and 31 reviews were 
excluded. Of the remaining articles, the full text was retrieved and assessed for eligibility. Six articles 
were further excluded based on an in vitro design (30), a study population aged below 18 years (31, 32), 
or involving cancer patients (33–35). Only 10 publications actually reported on the effect of 
thyrotoxicosis on haemostatic parameters and were therefore included in the present analysis (7, 9, 36–
43). In addition, we included one previously excluded publication from before June 2006 as the previous 
review did not take exogenous thyrotoxicosis into account (44). Taken together with the articles published 
before June 2006, a total of 29 articles were included. In several articles, more than one study or study 
design was described. The 29 articles contained a total of 51 studies: seven experimental studies (thyroid 
hormones given to healthy subjects) and 44 observational studies. The latter consisted of 15 intervention 
studies (pre- versus post-treatment in hyperthyroid patients) and 29 cross-sectional studies (hyperthyroid 
patients versus euthyroid controls).  Table 1 
Methodological quality of included studies 
Five observational cross-sectional studies, and 4 observational in- tervention studies of medium quality 
were identified. In the experimental studies, two high-quality studies and one mediumquality study were 
identified. The remaining studies were considered of low quality. 
Outcome parameters 
Observational cross-sectional studies 
Four medium quality studies involved subclinical thyrotoxicosis and only one study compared patients 
with overt hyperthyroidism to euthyroid controls. Levels of VWF, fibrinogen, and D-dimer were 
significantly increased in subclinical hyperthyroid individuals, whereas only fibrinogen levels were 
measured in overt hyperthyroid individuals and appeared to be slightly increased compared to euthyroid 
controls. Figure 1-2 
Observational intervention studies 
In the four medium quality studies, increased levels of plasma fibrinonectin, VWF, thrombomodulin and 
PAI-1, and decreased levels of tissue type-plasminogen activator (t-PA) were found during 
hyperthyroidism compared to the euthyroid state after normalization of thyroid hormone levels by anti-
thyroid agents. Figure 3 
Experimental studies 
Four studies investigated laboratory parameters in healthy volunteers taking thyroid hormone for a 
specific period of time. Thyrotoxicosis increased plasma levels of tissue factor, FVIII, FIX, VWF, 
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fibrinogen, d-dimer, and PAI-1. For the remaining parameters, no univocal statistical differences were 
observed. Figure 4 
 
Discussion 
This meta-analysis shows that thyrotoxicosis shifts the haemostatic balance towards a hypercoagulable 
and hypofibrinolytic state with a rise in FVIII, FIX, VWF, fibrinogen, and PAI-1. This was observed in 
both endogenous and exogenous thyrotoxicosis, and in subclinical as well as overt hyperthyroidism. 
Several pathophysiological mechanisms have been suggested to underlie the relation between thyroid 
hormone excess and haemostasis. One of these mechanisms is the activation of the immune system in 
thyroid disease (45, 46). As we found an equal effect on haemostatic parameters in subclinical 
thyrotoxicosis compared to overt thyrotoxicosis, the role of the immune system on the haemostatic system 
may be relevant. However, similar alterations were observed in exogenous thyrotoxicosis in which auto 
immunity does not come into play. This gives way for another possible mechanism involving the direct 
effect of thyroid hormones on the synthesis of coagulation and fibrinolytic proteins due to thyroid-
receptor mediated upregulation of gene transcription in hepatic and endothelial cells (47, 48). As antibody 
concentrations have been found to decrease with anti-thyroid treatment, these two mechanisms might not 
be mutually exclusive, but together may result in a prothrombotic state with an increased risk of both 
venous and arterial thrombosis during thyrotoxicosis (49, 50). Nowadays, thrombosis is known as a 
“multi-causal” disease in which multiple genetic or environmental risk factors coincide to push over a so-
called ‘thrombotic threshold’. If hyperthyroidism is a risk factor for venous thromboembolism (VTE), this 
will be clinically relevant both for the treatment and prevention of venous thrombosis as well as for the 
treatment of hyperthyroidism. It will be important for the distinction between provoked or unprovoked 
thrombosis and decisions on the duration of anticoagulant therapy. Moreover, it may lead to more vigilant 
monitoring for possible signs and symptoms of VTE in patients with recently diagnosed hyperthyroidism, 
but could also be relevant for prophylactic strategies in hyperthyroid patients undergoing surgery or other 
interventions associated with a high risk of venous thrombosis. In recent years, a few studies on the 
relationship between hyperthyroidism or thyroid hormone levels and VTE have been published  (51–58). 
Four population-based follow-up studies explored the risk of VTE in individuals with, amongst others, 
hyperthyroidism (51, 54, 55–57). The diagnosis of hyperthyroidism was, however, solely based on 
diagnostic codes. A recently performed cohort study, performed by our group, included a small number of 
patients with biochemically confirmed overt hyperthyroidism (53). Two case-control studies investigated 
the risk of VTE associated with varying levels of thyroid hormone (52, 56). A rise in VTE risk was found 
with higher levels of thyroid hormone, yet only a small number of patients had thyroid levels above the 
upper end of the normal range. These studies mostly point towards an increased risk of VTE associated 
with hyperthyroidism. However, limitations due to study design and contradicting results drastically 
reduce the strength of evidence and do not allow for definitive conclusions to be drawn about the clinical 
relevance of the findings. Further prospective studies are needed to provide robust evidence on the VTE 
risk involved in hyperthyroidism, and subsequently the mechanisms behind this presumed relationship. 
Ideally, a prospective clinical study including consecutive patients with a well-defined degree of 
hyperthyroidism, with proven VTE as main outcome should be performed. In addition, further insight 
could be obtained by assessing the relation between thyroid hormone levels and venous thrombosis in 
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patients already at high risk of venous thrombosis, such as patients undergoing major orthopaedic 
surgery. Several limitations need to be addressed. Most importantly, the use of quality scoring in meta-
analysis for observational studies is controversial. Also, the quality scoring is arbitrary. However, we do 
feel that it is the only way to gain insight on adequate study design and identify risks of bias. Even when 
combining the more recent studies (published after June 2006) with the older studies, only a limited 
number of medium and high-quality studies were found. As a result, most observed alterations have not 
been confirmed in other studies. However, we were able to confirm main alterations in different study 
designs, and most low-quality studies provided similar results. 
In conclusion, this meta-analysis showed consistent evidence of a hypercoagulable and hypofibrinolytic 
state in thyrotoxicosis. Well-designed studies with clinical outcomes are needed to provide more 
definitive data. Only then, the clinical relevance of these findings, especially in terms of prevention and 
treatment of venous thrombosis in hyperthyroid patients, can be determined. 
 
Table 1: Characteristics of included studies 
Author Study design Quality Population 
(n) 
Treatmen
t or 
interventi
on 
Blood 
sampling 
Outcome 
parameters 
Arnaout, 
1992 
A. 
Observational
: 
Cross-
sectional 
B. 
Observational
: 
Intervention 
low Hyperthyroid 
patients (12) 
Euthyroid 
controls (15) 
Hyperthyroid 
patients (10) 
 
 
 
Anti-
thyroid 
treatment 
A.Before 
start of 
treatment 
 
B.Before 
treatment 
and after 
euthyroidis
m 
wasachieved 
A.pFN, 
FVIII:C, 
vWF:Ag, AT-III 
1antitrypsin:A
g 
 
B.pFN, FVIII:C, 
vWF:Ag, AT-III 
1antitrypsin:A
g 
Burggraaf, 
2001 
A. 
Observational
: 
Cross-
sectional 
B. 
Observational
: 
Intervention 
low 
 
 
medium 
A.Hyperthyroi
d patients (14) 
Euthyroid 
controls (14) 
B.Hyperthyroi
d patients (14) 
 
 
 
B.Propran
olol and 
thiamazol 
10 mg 3 
times a 
day and 
levothyrox
ine 
100 ug 
starting 
dose 
ABefore 
start of 
treatment 
 
B At time of 
diagnosis 
and 
after 
euthyroidis
m was 
achieved (at 
least 1 
months 
after 
propranol 
was 
stopped) 
F1+2, cFN, 
pFN, VWF:Ag, 
tPA:Ag, tPA:C, 
PAI-1:Ag, 
PAP, 
thrombomoduli
n, Plasminogen, 
-2-
antiplasmine, 
Fibrinogen: 
Ag, 
 
Coban, Observational
: 
mediun Subclinical 
hyperthyroid 
 Before start VWF:Ag 
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2006 Cross-
sectional 
patients (20) 
Euthyroid 
controls (20) 
of treatment 
Dörr, 
2005 
A 
Observational
: 
Cross-
sectional 
 
B. 
Observational
: 
Cross-
sectional 
medium A General 
population of 
unselected 
patients 
divided 
into TSH<0.1 
mU/l (11) 
compared to 
TSH 0.3–3.0 
mU/l (3362) 
B .General 
population of 
unselected 
patients 
divided 
into TSH<0.3 
mU/l (388) 
compared to 
TSH 0.3–3.0 
mU/l (3362) 
  Fibrinogen:Ag 
Erem, 
2002 
Observational
: 
Cross-
sectional 
low Hyperthyroid 
patients (41) 
Euthyroid 
controls (20) 
 Before start 
of treatment 
PT, APTT, 
Fibrinogen, 
FV:C, 
FVII:C, 
FVIII:C, FIX:C, 
FX:C, 
AT III:Ag, 
Protein C (%), 
Protein S, 
vWF:C, t-
PA:Ag, 
PAI-1:Ag 
Erem, 
2006 
Observational
: 
Cross-
sectional 
low Subclinical 
hyperthyroid 
patients (20) 
Euthyroid 
controls (20) 
 Before start 
of treatment 
Platelet count, 
MPV, PT, 
APTT 
Fibrinogen:Ag, 
D-Dimer, 
FV:C, FVII:C, 
FVIII:C, FIX:C, 
FX:C, AT-
III:Ag, Protein 
C, 
Protein S, 
VWF:C,t-
PA:Ag, 
PAI-1:Ag 
Graninger, 
1986 
A. 
Observational
: 
Cross-
sectional 
B. 
Observational
: 
A. low 
B.mediu
m 
A. 
Hyperthyroid 
women (27) 
Euthyroid 
women (30) 
B.Healthy 
women (7) 
 
 
B. 25 ug 
T3 three 
times a 
day for 14 
days 
A.Before 
start of 
treatment 
B. On day 
4,7, 14 and 
24 after 
start of 
pFN, FVIII:Ag, 
AT-III:Ag 
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Intervention treatment 
 
Li, 1998 A. 
Observational
: 
Cross-
sectional 
B. 
Observational
: 
Intervention 
A. low 
B.mediu
m 
A. 
Hyperthyroid 
patients (14) 
Euthyroid 
controls (10) 
B. 
Hyperthyroid 
patients (14) 
 
 
B. Iodine 
radiothera
py 
A. Before 
start of 
treatment 
B. Before 
and 30 days 
after 
treatment 
vWF:Ag, t-
PA:ag, PAI-
1:Ag 
Liu, 1993 A. 
Observational
: 
Cross-
sectional 
B. 
Observational
: 
Intervention 
A. low 
B.mediu
m 
A. 
Hyperthyroid 
patients (35) 
Euthyroid 
controls (20) 
B.Hyperthyroi
d patients (7) 
B. Anti-
thyroid 
treatment 
A. Before 
treatment 
B. Before 
treatment 
and after 
euthyroidis
m was 
achieved 
VWF:Ag 
Marongiu, 
1988 
Observational
: 
Cross-
sectional 
low Hyperthyroid 
patients (14) 
Euthyroid 
controls (25) 
 One time 
point 
Fibrinopeptide 
B15–42 
Fibrinogen: 
C 
Marongiu, 
1991 
Observational
: 
Cross-
sectional 
low Hyperthyroid 
patients (65) 
Euthyroid 
controls (58) 
 One time 
point 
Fibrinopeptide 
a, GLP, MLP 
Marongiu, 
1991 
A. 
Observational
: 
Cross-
sectional 
B. 
Observational
: 
Intervention 
low A. 
Hyperthyroid 
patients (50) 
Euthyroid 
controls (14) 
B. 
Hyperthyroid 
patients (40) 
 
 
B. 
Methimaz
ole or 
131I 
treatment 
A. Before 
start of 
treatment 
B. Before 
treatment 
and after 
euthyroidis
m was 
achieved 
fibrinopeptide a, 
fibrinopeptide 
B15–42, 
Fibrinogen:C 
Morishita, 
1998 
A. 
Observational
: 
Cross-
sectional 
B. 
Observational
: 
Intervention 
low A. 
Hyperthyroid 
patients (15) 
Euthyroid 
controls (25) 
B. 
Hyperthyroid 
patients (10) 
 
 
 
B 
Antithyroi
d drugs 
A. Before 
start of 
treatment 
B. Before 
treatment 
and after 
euthyroidis
m was 
achieved 
vWF:Ag, 
thrombomoduli
n, 
Free TFPI, Total 
TFPI 
Myrup, 
1995 
A. 
Observational
: 
A. low 
B.mediu
A. 
Hyperthyroid 
patients (10) 
 
 
A. Before 
start of 
Platelets, 
Bleeding time, 
RIPA, Platelet 
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Cross-
sectional 
B. 
Observational
: 
Intervention 
m Euthyroid 
controls (15) 
B. 
Hyperthyroid 
patients (10) 
B. 
Carbimazo
le 
treatment 
B. Before 
treatment 
and after 
euthyroidis
m was 
achieved 
aggregation 
(ADP/collagen), 
pFN, 
vWF:Ag, 
Fibrinogen:Ag, 
-2 
macroglobulin 
Ozcan, 
2003 
A. 
Observational
: 
Cross-
sectional 
B 
Observational
: 
Intervention 
low A 
Hyperthyroid 
patients (10) 
Euthyroid 
controls (16) 
B 
Hyperthyroid 
patients (10) 
 
B Anti-
thyroid 
therapy 
(not 
further 
specified) 
A. Before 
start of 
treatment 
B. Before 
treatment 
and after 
euthyroidis
m was 
achieved 
free TFPI, total 
TFPI, tPA:Ag, 
PAI-1:Ag 
Rogers, 
1982 
A. 
Observational
: 
Cross-
sectional 
B. 
Observational
: 
Intervention 
low A 
Hyperthyroid 
patients (22) 
Euthyroid 
controls (24) 
B 
Hyperthyroid 
patients(10) 
 
B. 
Levothyro
xine, 
radioactive 
iodine, 
propylthio
uracil 
A. Before 
start of 
treatment 
B. Before 
treatment 
and after 
euthyroidis
m was 
achieved 
FVIII:C, 
FVIII:Ag: 
FVIII:RiCo 
Rosc, 
1998 
Observational
: 
Cross-
sectional 
low Hyperthyroid 
patients (33) 
Euthyroid 
controls (34) 
 Before start 
of treatment 
t-PA:Ag, u-
PA:Ag, PAI-
1;Ag 
Wahrenbe
rg, 2002 
A. 
Observational
: 
Cross-
sectional 
B. 
Observational
: 
Intervention 
low A 
Hyperthyroid 
patients (10) 
Euthyroid 
controls (16) 
BHyperthyroi
d patients (10) 
 
B Anti-
thyroid 
therapy 
for at least 
8 
weeks (not 
further 
specified) 
A. Before 
start of 
treatment 
B. Before 
treatment 
and after 
euthyroidis
m was 
achieved 
PAI-1:C, PAI-
1:Ag 
Rogers, 
1983 
Experimental: 
Clinical trial 
medium Healthy 
volunteers (14 
and 9) 
A. 
Levothyro
xine (LT4) 
0.6 mg 
daily 
B. 
Liothyroni
ne 50 ug 
three times 
A. On day 
1,7 and day 
14 
B. On day 1 
and 7 
FVIII:C, 
FVIII:Ag: 
FVIII:RiCo 
 25 
daily 
Akinci, 
2007 
Observational
: 
Cross-
sectional 
low Overt 
hyperthyroid 
patients 
(14) 
Euthyroid 
controls (26) 
 Before start 
of treatment 
PAI-1:Ag, 
TAFI:Ag 
Akinci, 
2011 
A.Observatio
nal: 
Cross-
sectional 
B. 
Experimental: 
Clinical trial 
A low 
B 
medium 
A. Subclinical 
hyperthyroid 
patients 
(10) euthyroid 
controsl 
(18) 
B 
Premenopausa
l women 
with benign 
thyroid 
nodules 
(20) 
 
 
B 
Levothyro
xine (LT4) 
suppressio
n 
therapy 
A. Before 
start of 
treatment 
B Before 
and one year 
after 
LT4 
suppression 
therapy 
PAI-1:Ag, 
TAFI:Ag 
Brona, 
2011 
 
Observational
: Intervention 
low Overt and 
subclinical 
hyperthyroid 
women (15 
and 20) 
Radioiodin
e 
therapy 
Before 
treatment, 
and between 
24–28 or 12-
16 weeks 
after 
treatment 
Fibrinogen:C, 
D-Dimer 
Coban, 
2008 
Observational
: 
Cross-
sectional 
Medium SC 
hyperthyroid 
patients 
(36) 
Euthyroid 
controls (36) 
 One time 
point 
Fibrinogen:C, 
D-Dimer 
Demir, 
2009 
Experimental: 
Clinical trial 
High Premenopausa
l women 
with benign 
thyroid 
nodules 
(30) 
Levothyro
xine (LT4) 
suppressio
n 
therapy 
Before and 
one year 
after 
start of LT4 
suppression 
therapy 
Fibrinogen :C, 
D-Dimer, 
vWF:C, Tissue 
Factor, 
t-PA:C, PAI-
1:Ag, TFPI:Ag 
Erem, 
2009 
Observational
: 
Cross-
sectional 
low Hyperthyroid 
patients (30) 
healthy 
controls (25) 
 Before start 
of treatment 
FV:C, Protein 
C, Protein S, 
TFPI:Ag, 
TAFI:Ag 
Homoncik
, 2007 
A. 
Observational 
Crossectional 
B. 
Observational 
Intervention 
 AOvert 
hyperthyroid 
patients 
(30) 
Euthyroid 
controls (30) 
B Overt 
hyperthyroid 
patients 
(30) 
 
B 
Thiamazol
e started 
with 60 
mg/d 
adjusted 
depending 
on T4, T3 
and TSH 
concentrati
A One time 
point 
B At 
baseline and 
after therapy 
with 
thiamazole 
Platelet count, 
PT, APTT, 
platelet 
aggregation 
(epinephrine), 
vWF:Ag, 
vWFRiCo, 
FVIII:C 
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ons 
Lippi, 
2008 
Observational
: 
Cross-
sectional 
medium General 
population of 
unselected 
patients 
devided 
into TSH<0.2 
(54) compared 
to TSH 0.2–
2.5 (943) 
 Retrospectiv
e analysis of 
routine 
blood testing 
APTT, PT, 
Fibrinogen:C 
Mohamed
-Ali, 2008 
Observational
: 
Cross-
sectional 
 Overt  and 
subclinical 
hyperthyroid 
patients 
(30) 
Euthyroid 
controls (30) 
 Before start 
of treatment 
Platelet count, 
PT, APTT, 
Fibrinogen: 
Ag 
Van 
Zaane, 
2010 
Experimental: 
Randomised 
clinical 
trial 
High A Healthy 
volunteers 
(16) 
B Healthy 
volunteers 
(12) 
A 
Levothyro
xine 0.3 
mg/d or 
placebo 
for 14 days 
B 
Levothyro
xine 0.45 
mg/d or 
0.6 mg/d 
depending 
on 
weight or 
placebo 
for 14 days 
At baseline 
and on day 
14 
PT, APTT, 
Fibrinogen:Ag, 
VWF:Ag, 
VWF:RiCo (%), 
Factor II:C, 
FVII:C, 
FVIII:C,FIX:C, 
FX:C, protein 
C, APCsr, total 
protein S, 
free protein S, 
F1+2, ETP, 
PAI-1:Ag, PAP, 
D-dimer, 
Clot-lysis time 
PT indicates protrombin time; APTT, activated partial thromboplastin time; ADP, adenosine 5’-
diphosphate; RIPA, ristocetin platelet agglutination; F1+2, prothrombin fragment 1+2; pFN, plasma 
fibronectin; cFN, cellulair fibronectin; F, factor; Ag, antigen; C, activity; RiCo, ristocetin-cofactor 
activity; VWF, von Willebrand factor; ATIII, antithrombin III C; GPL, anti-cardiolipin antibody IgG; 
MLP, anti-cardiolipin antibody IgM; TFPI, tissue factor pathway inhibitor; TAFI, thrombin-activatable 
fibrinolysis inhibitor; PAP plasmin-antiplasmin complexes; t-PA, tissue type-plasminogen activator; u-
PA, urokinase-type plasminogen activator; PAI, plasminogen activator inhibitor; ETP, endogenous 
thrombin potential; APCsr, activated protein C sensitivity ratio 
 
Fig.1 Haemostatic parameters for all medium-/high-quality cross-sectional studies: subclinical 
hyperthyroidism 
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Fig. 2 Haemostatic parameters for all medium-/high-quality cross-sectional studies: overt 
hyperthyroidism 
 
 
Fig 3 Haemostatic parameters for all medium-/high-quality observational intervention studies 
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Fig  4 Haemostatic parameters for all medium-/high-quality experimental studies 
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Gravidanza  
Durante la gravidanza il rischio di sviluppare trombosi venosa aumenta di dieci volte, 
probabilmente come conseguenza dell’attivazione del sistema emostatico, della 
riduzione del ritorno venoso e della riduzione del sistema fibrinolitico che si sviluppano 
durante la gestazione24. Inoltre anche  gravidanze multiple, età maggiore di 35 anni e 
l’obesità possono essere considerati fattori di rischio per lo sviluppo di trombosi in 
gravidanza.25 La patologia tromboembolica comunque rappresenta la prima causa di 
morte materna nei paesi occidentali e anche durante il puerperio il rischio trombotico è 
cinque volte maggiore rispetto a donne di pari età26. 
In letteratura si ritrovano diverse linee guida circa la terapia anticoagulante in 
gravidanza, ma i dati riguardano poche  pazienti  che spesso trattate per patologie 
diverse dalla trombosi venosa.  
Quindi in considerazione della rilevanza clinica e della mancanza di dati certi 
sull’argomento, abbiamo deciso di condurre una revisione sistematica della letteratura 
riguardo il trattamento della tromboembolia in gravidanza. Utilizzando i motori di ricerca 
EMBASE e MEDLINE sono stati identificati gli studi riguardanti la terapia 
anticoagulante attuata per un episodio di tromboembolismo venoso verificatosi in 
gravidanza, la ricerca è stata poi completata considerando gli abstracts congressuali. 
Sono stati identificati più di 5000 articoli, ma sono stati selezionati per le analisi 15 
articoli e 3 abstracts. In totale sono stati evidenziati 981 casi di pazienti  affette da 
trombosi venosa profonda o embolia polmonare durante la gravidanza. Per la maggior 
parte la terapia di scelta è stata rappresentata da eparina a basso peso molecolare che 
si è dimostrata efficace ed anche sicura in questa particolare popolazione di pazienti; 
                                                 
24
 Rodger MA, Walker M, Wells PS. Diagnosis and treatment of venous 
thromboembolism in pregnancy. Best Pract Res Clin Haematol 2003; 16:279-96  
Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 114:409-14 
25
 Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural 
changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 
1997; 104: 191-7 
Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J med 
2008; 359: 2025-33 
26Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum 
period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J 
Thromb Haemost. 2008 Apr;6(4):632-7 
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infatti il rischio emorragico non si è discostato da quello rilevato in pazienti trattati per 
patologia trombotica non in corso di gravidanza. 
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Introduction 
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism 
(PE), is one of the most relevant causes of maternal death in the developed countries with a reported 
mortality rate of 1.56 per 100,000 maternities in the United Kingdom [1,2]. Symptomatic VTE is 
estimated to occur in 5 to 12 women per 10,000 pregnancies ante-partum and in 3 to 7 women per 10,000 
deliveries post-partum [3,4]. During pregnancy and puerperium, the risk of developing VTE is five times 
higher than in the general female population of childbearing age [5].  
Treatment of VTE in pregnant women poses some particular challenges, because it requires taking into 
account the safety of the selected drugs not only for the mother, but also for the fetus. Vitamin K 
antagonists (VKAs) cross the placenta and have the potential to cause fetal bleeding and teratogenicity[ 
6]. Unfractionated heparin (UFH) does not cross the placenta and does not cause fetal teratogenicity, but 
its use may be associated with additional maternal safety issues including the risk of heparin-induced 
thrombocytopenia (HIT) and heparin-associated osteoporosis [6]. Furthermore, the use of therapeutic 
doses of UFH requires regular laboratory monitoring of the activated partial thromboplastin time (aPTT). 
As UFH, low-molecular weight heparin (LMWH) does not cross the placenta and there is no evidence of 
teratogenicity or risk of fetal bleeding [6,7]. In addition, LMWH offers a number of advantages over UFH 
thanks to its better bioavailability, longer plasma half-life, more predictable dose response and improved 
safety profile with respect to osteoporosis and HIT [6]. For these reasons, LMWH is currently 
recommended as the treatment of choice for patients with acute VTE occurring during pregnancy [2-4,6-
10]. However, evidence to support this recommendation is largely based on case reports or case series of 
pregnant patients, or on data derived from studies carried out in non-pregnant patients. Consequently, 
limited data exist on the incidence rate of recurrent VTE or bleeding during treatment with LMWH or 
UFH during pregnancy and puerperium, and little is known on their optimal therapeutic dosage. Thus, 
different therapeutic strategies are proposed and used in clinical practice. [3,6,8,9]. Although a few 
systematic and narrative reviews have tried to assess the risk to benefit profile of anticoagulant treatment 
of VTE in pregnancy [3,9,10,11], these studies often mixed together data from patients receiving 
anticoagulant therapy for different indications such as VTE treatment or prophylaxis, prevention of 
obstetrical complications, prevention of arterial thrombosis in patients with mechanical cardiac valves or, 
conversely, only focused on a single therapeutic agent. 
We therefore decided to carry out a systematic review of the literature and a meta-analysis of the studies 
that have reported on recurrent VTE or bleeding events in patients receiving anticoagulant drugs for the 
treatment of pregnancy related VTE with the aim to provide an estimate of the incidence rates of these 
complications. 
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Methods 
A protocol was prospectively developed. Specific objectives, criteria for study selection, approach to 
assess study quality, outcomes, and statistical methods were a priori defined. 
Study identification 
Studies were identified using the MEDLINE (1966 to April Week 2 2012) and EMBASE (1980  to April 
Week 2 2012) electronic databases. The search strategy was developed using the following keywords: 
“Venous Thrombosis”, “Pulmonary Embolism”, “Pregnancy”, “Therapy”, “Treatment”.  
The electronic search was supplemented by manual search of reference lists and recent reviews and by 
reviewing abstracts books from the Congress abstracts from the International Society on Thrombosis and 
Haemostasis (ISTH) annual meetings, from the European Society of Human Reproduction and 
Embryology (ESHRE) annual meetings, and from the American Society of Haematology (ASH) meetings 
from 2003 to 2011. 
Studies were selected if they reported data about recurrent VTE (any PE or DVT) and/or about any 
haemorrhagic event  that occurred during pregnancy or the post-partum periods.  
Study selection 
Study selection was performed independently by 2 reviewers (ERo, ERa), with disagreements resolved 
through discussion and by the opinion of a third reviewer (FD), if necessary.  Any type of randomised 
controlled trials or cohort studies were included if they met the following criteria: I) deep venous 
thrombosis (DVT) or pulmonary embolism (PE) were objectively confirmed (with Doppler ultrasound, 
computer tomography, angiography, lung scan) and occurred during pregnancy; II) patients were treated 
with one or more anticoagulant drug.  
We excluded studies that considered VTE occurring before pregnancy, studies in which pregnant women 
were treated for reasons other than the treatment of acute VTE, and when it was impossible to obtain 
separate data about patients treated for acute VTE only.  
To reduce the risk of biased results, we decided to only include studies that enrolled more than 10 
patients. 
When multiple publications for a single study had been published, we decided to use the latest publication 
and to supplement it, if necessary, with data from the earlier publications. 
To assess the agreement between reviewers for study selection, we used the k statistic, which measures 
agreement beyond chance [12].  Values higher than 0.6 were considered to represent a substantial 
agreement and values higher than 0.8 an almost perfect agreement. 
Data Extraction 
Two reviewers (ERo, ERa) independently completed data extraction using a standardized form. 
Disagreement was resolved by consensus and by the opinion of a third reviewer (FD), if necessary.  
The following data were extracted: study characteristics (year of publication, design, study centre), 
patients characteristics (number of subjects studied, mean age, mean gestational age at diagnosis of VTE), 
number of DVT and PE events, drugs and regimens used for the acute treatment, drugs and regimens used 
for the long-term treatment, haemorrhagic events occurred both ante-partum and during post-partum 
period, recurrent VTE events occurred both ante-partum and during post-partum period.  
The acute treatment phase was defined as the first week of anticoagulant therapy, the long-term treatment 
period was defined as the remaining treatment period.   
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To define the severity of bleeding events, we aimed to use the ISTH classification for haemorrhages 
occurred during the ante-partum period [13] . Post-partum haemorrhage (PPH) was defined as those 
bleeding events occurring within the first 24 hours after delivery and we aimed to use the classification 
proposed by the Royal College of Obstetricians and Gynaecologists (RCOG)[14]. Based on this 
definition, major PPH is adjudicated after the loss of 1000 ml or more of blood from the genital tract; 
clinically relevant, non- major bleeding after the loss of more than 500 ml of blood; and minor bleeding in 
case on any other blood loss reported. In the case the quantity of blood loss was not specified, we took 
into account the definition of bleeding given by the authors and considered wound haematomas as minor 
bleedings and atonic post-partum bleedings as clinically relevant, non-major bleedings. In addition, we 
aimed to collect information about bleeding that occurred after the first 24 hours from the delivery and to 
classify again using the ISTH definitions in the absence of other available classifications. 
We considered recurrent VTE as any new thromboembolic event occurred during anticoagulant therapy 
and after the index VTE, as adjudicated by the authors.   In addition, information was collected on the 
occurrence of heparin induced thrombocytopenia (HIT) during treatment. In case of necessity we 
contacted the authors for additional information. 
Study Validity Assessment 
A protocol was prospectively developed. Specific objectives, criteria for study selection, approach to 
assess study quality, outcomes, and statistical methods were a priori defined and reported according to 
the  proposal for reporting of Meta-analysis of Observational Studies in Epidemiology (MOOSE) group 
[15]. The same 2 unmasked investigators independently completed the assessment of study validity. We 
assess the methodological quality of each study with the Newcastle-Ottawa scale that was developed to 
assess the quality of non-randomised studies with its design, content and ease of use directed to the task 
of incorporating the quality assessments in the interpretation of meta-analytic results [16] . A 'star system' 
was developed for this scale in which a study is judged on three broad perspectives: the selection of the 
study groups; the comparability of the groups; and the ascertainment of either the exposure or outcome of 
interest for case-control or cohort studies respectively [16]. We awarded studies a maximum of 3 points 
for selection, 2 points for comparability, and 2 points for outcome assessment, with more points 
indicating better quality. The maximum possible score was 7: studies that obtained 6 or 7 points were 
considered of high quality, studies that obtained 3 or less points of low quality and the others studies were 
considered of medium quality.  
The quality scale was supplemented by other quality criteria that were specific for this study: description 
of the methods used for the diagnosis of VTE (how was the diagnosis made in each study), definition of 
recurrence, and the use of standardized methods for determining haemorrhage.  
Statistical analysis 
Weighted mean incidence of bleeding complications and of VTE recurrence were calculated using the 
random effect model [17] Events occurring during the ante-partum and post-partum period were analyzed 
separately. Statistical heterogeneity was evaluated using the Cochran’s Q and  the I2 statistic [18]. 
Analysis was performed with StatsDirect software (Version 2.7; StatsDirect Ltd, England).   
Results 
A total of 5011 (2831 Medline 2180 Embase) citations, 6 abstracts from ISTH and 2 abstracts from ASH 
meetings were identified by our systematic search. A total of 4988 studies, 3 ISTH abstracts and 2 ASH 
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abstracts were excluded after reviewing the study titles or abstracts. We subsequently retrieved the full 
text of 31 potentially eligible articles and 3 ISTH abstracts. Among the studies published as full papers, 
we further excluded 1 article because no antithrombotic therapy was used, 7 because they included 10 or 
less patients, 2 because no data about follow-up were provided, and 6 because data on patients treated for 
acute VTE were undistinguishable from data on women receiving antithrombotic prophylaxis. Thus, a 
total of 15 full papers [19,20,22-26,28-30,32-36] and 3 abstracts [21,27,31] were eligible for inclusion in 
our systematic review. (Figure 1) 
The inter-observer agreement for the study selection was optimal (k=0.91). 
According to the Newcastle-Ottawa scale, no studies were of high quality and four studies were of 
medium quality [26,29,33,36]. Eight studies specified that diagnosis of VTE was made using imaging 
techniques [20,22,24,26,28,30,35,36], two studies defined the diagnosis of recurrent VTE [20,35] and 
only one study used the classical definition of PPH to describe post-partum haemorrhages [33]. 
Among the selected studies, 17 were written in English [19,21-36] and 1 in German [20].  
The corresponding authors of 11 of the selected studies were contacted with the aim to receive missing 
information and 6 authors kindly provided the requested data.  
A total of 981 pregnant women with acute VTE were included, with their age ranging from a minimum of 
17 years to a maximum of 43 years. Only 13 of the selected studies, including a total of 632 patients, 
provided separate data on the number of DVT and PE (in total: 506 DVT and 127 PE) [19,20,22,24-
28,31-33,35,36.] (Table 1). The timing of VTE onset during pregnancy was not reported in all studies. 
Where available, this ranged from the 7th gestational week to the 38th gestational week.  
Overall, 822 patients received LMWH and 155 UFH for the acute phase treatment of VTE. None of the 
studies reporting on patients treated with fondaparinux met our selection criteria. Dosing regimens of 
LMWH were heterogeneous among studies and are summarized in Table 2. Only in two studies, during 
the acute phase, the dosages were adjusted according to the measurement of anti-Xa levels [26,35].  UFH 
was administered both intravenously and subcutaneously, in most cases, but not always, according to 
aPTT values. (Table 2) 
Treatment regimens during the long-term treatment period are summarised in Table 3. The majority of 
patients initially treated with UFH were switched to LMWH, others were continued on UFH, in most 
cases administered subcutaneously, and a few (36 from a single study[22]) were switched to warfarin. In 
one study, 4 patients initially treated with LMWH were switched to UFH during the late phase of 
pregnancy[36]. During the long-term treatment period, six studies reported on dose changes to LMWH 
according to anti-Xa levels in some patients [26,31,32,34-36] 
Duration of the follow-up period was heterogeneous among studies and, in some cases, it was not 
reported. In one study, follow-up was limited to the first three months after the diagnosis of VTE[22]. 
Based on information provided, we could not estimate the total duration of treatment period.  
Bleeding complications in the ante-partum period  
During the ante-partum period, a total of 28 bleeding events were reported in 16 studies over a total of 
944 patients [19,21-24, 26-36]. Regrettably, available data were not sufficient to enable us to apply the 
ISTH classification of bleeding severity, so we could only use the definitions given by the authors in each 
study. Overall, 5 events were defined by the authors as major, 1 was defined as clinically relevant non-
major, 16 were defined as minor, and 6 events were not classified [29-30]. In one patient major bleeding 
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developed after severe eclampsia complicated by thrombocytopenia [31]. Four of the 5 major bleedings 
occurred during the acute phase treatment 19,22, and the only 1 clinically relevant non-major bleeding after 
2 weeks of treatment [28]. Of the 4 major bleeding events that occurred during the acute phase treatment, 
2 occurred in patients treated with LMWH and 2 in patients treated with UFH.  
The use of anticoagulant therapy was therefore associated with an ante-partum incidence of haemorrhagic 
complications of 3.28% (95% CI:2.10-4.72;I2 : 14.6%). The ante-partum incidence of major bleeding was 
1.41 % (95% CI:0.60-2.41;I2:0%); the incidence of major bleeding during the acute treatment phase only 
was 1.00 % (95% CI:0.4-2.0%;I2:0% ) (Figure 2). Based on available data, it was not possible to 
separately estimate the incidence of bleeding complications for UFH and LMWH.   
Bleeding complications in the post-partum period 
A total of 260 PPH were reported in 13 studies [21,23-29,31-33,35,36], over a total of 725 patients. In 
most studies, information on blood losses was sufficient to enable us to use the classification of the 
RCOG. In total, 14 PPH were defined as major, 41 were defined as clinically relevant non-major (4 of 
these were atonic post-partum bleedings), and 205 were defined as minor. (Table 4)  
The incidence of major PPH was 1.90% (95% CI:0.80-3.60%; I2:36.8%). (Table 5, Figure 2) 
Only 7 studies with a total of 350 patients provided information on bleeding events occurring after the 
first 24 hours after delivery. Information provided on bleeding events was insufficient to apply any 
classification, and the definition of severity provided by the authors was used. Information on the duration 
of follow-up was not available. A total of 14 haemorrhagic events were reported: 3 were defined as major 
(1.2%, 95% CI:0.30-2.50%; I2:0%)  
 
Thromboembolic complications 
Information on recurrent venous thromboembolic events occurred during the ante-partum period was 
available in 16 studies including a total of 922 patients. There were 16 recurrent VTE events: 11 were PE 
(one fatal) and 5 were DVT. (Table 4)  
The estimated weighted-mean incidence of ante-partum recurrent VTE was 1.97% (95% CI:0.88-3.49% 
I2: 39.5%).(Figure 3) The estimated weighted mean incidence of recurrent PE was 1.30 % (95%CI: 0.6 
%-2.3%; I2 13.3%). 
Seven VTE recurrences occurred in the first 7 days after the start of treatment, 5 of these occurred on 
UFH treatment [19,20,23,27].  
The incidence rate of recurrent VTE during the acute phase treatment period was 1.41% (95%CI: 0.44-
2.90%; I2 38%); during the long-term treatment period this incidence was 0.95% (95%CI: 0.37-1.82%; 
I2:0%). Once again, based on available data we could not separately estimate the incidence of bleeding 
complications for UFH and LMWH. 
Two studies [19,23], including 41 patients, reported on 4 cases of recurrent VTE occurred during the 
post-partum period.  
Finally, we found no reported cases of HIT in the 13 studies that addressed this complication, for a total 
of 860 patients. [21-24,26-29,31,32,34-36]. The occurrence of HIT was prospectively assessed in only 2 
studies. 
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Discussion 
The results of this systematic review of the literature substantially support the efficacy and safety of 
currently used therapeutic strategies for the treatment of pregnancy-related VTE, but suggest that some 
work should be done to improve their efficacy and safety profile, in particular during the highest risk 
periods. In fact, the estimated incidence of recurrent events during pregnancy remains substantial during 
the first week of treatment, as well as the rates of major bleeding complications, again during the first 
week of treatment and in the first 24 hours after delivery.  
We observed a substantial heterogeneity in the reported treatment regimens: although most patients 
received LMWH, various dosing regimens for the acute phase treatment and, in particular, for the long-
term secondary prevention were prescribed in the studies, and no direct comparisons are currently 
available. Heterogeneity was also present among definitions of major bleeding events prior and after 
delivery in individual studies. Because the application of a single, more widely accepted definition was 
not always feasible given the limited information provided in some studies, the observed rates of bleeding 
should be interpreted cautiously.  
The 2012 version of the guidelines of the American College of Chest Physicians (ACCP) recommends the 
use of adjusted-dose LMWH for the treatment of VTE during pregnancy [6.] LMWH is considered the 
best option based on its greater bioavailability and its favourable safety profile. It is also recommended 
that anticoagulant therapy should be continued with the same dose throughout pregnancy, and until at 
least 6 weeks after delivery [6]. Clear-cut indications about the need for dose adjustments over the course 
of pregnancy or the usefulness of routine measurement of anti-Xa activity were not provided [6]. In the 
RCOG guidelines published in February 2007 [2], the authors suggested to treat VTE with LMWH given 
twice daily throughout pregnancy and discouraged physicians from the routine measurement of peak anti-
Xa activity, with the exception of women at extremes of body weight or with other complicating factors 
like renal insufficiency. In our search, we found six studies in which, in some patients, the LMWH 
dosages were modified according to anti-Xa levels. Unfortunately, a separate assessment of clinical 
outcomes in this subgroup of patients was not feasible. During the acute phase treatment period, most 
patients have received weight-adjusted, full dose LMWH with an acceptable incidence of major bleeding 
events; during the long-term treatment phase period, in most patients treatment doses were empirically 
reduced, while a minority of patients have received dose adjustments based on the measurement of anti-
Xa levels.  
Of note, the rates of major bleeding events in our study are consistent with the rates of major bleeding 
events reported in studies carried out in non-pregnant patients treated for acute VTE with standard 
anticoagulant therapy [4,37]. Conversely, the estimated incidences of bleeding and recurrent VTE events 
in our study somewhat differ from the results of a previous systematic review published in 2005 by Greer 
et al. [9]. In this study, the authors assessed the safety and the efficacy of LMWH during pregnancy, and 
included both patients treated for pregnancy-related DVT or PE (n: 146) and patients receiving 
antithombotic prophylaxis. The overall rate of what the authors defined significant bleeding was 1.98% 
(95% CI: 1.50%-2.57%) including both the ante-partum and the post-partum periods, and 0.43% (95% 
CI: 0.22%-0.75%) in the ante-natal period only. The rate of bleeding in the post-partum period only in 
patients on LMWH for the treatment of acute VTE was 1.72%. These rates are lower than the rates 
reported in our study, probably because we included only patients receiving therapeutic doses of 
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anticoagulants and patients on UFH, and possibly because of a different definition of bleeding events. 
Finally, also the rates of recurrent VTE in our study were higher than those reported in the review by 
Greer et al (1.15%).  
Our meta-analysis has a number of limitations. First, only case-control and cohort studies have been 
published, and the application of formal meta-analytic methods to observational studies is controversial, 
since bias implicit in the study design may misrepresent the strength of associations within the data [12]. 
In addition, we considered studies with different end-points and with different durations of follow up. 
Moreover, the therapeutic strategies were highly heterogeneous among studies, and different compounds 
with different dosing regimens were used. Unfortunately, separate analysis of these therapeutic regimens 
was not feasible due to the insufficient information provided in the selected studies. Another limitation is 
in the lack of standardized definitions of bleeding severity among selected studies, which mandates some 
caution when interpreting the reported figures. This in particular applies to the definition of PPH. PPH is 
traditionally defined as any blood loss from the genital tract during delivery above 500ml [13,14,38], but 
other definitions also required the presence of clinical signs of blood loss [39]. Furthermore, we could not 
obtain data related to the entire duration of the puerperium; firstly because of the wide variability in 
follow up durations among the selected studies, secondly because in most studies data on anticoagulant 
treatment and on related complications after the delivery were not provided. Similarly, the criteria used to 
diagnose recurrent VTE were not reported in most studies, and it is possible that some heterogeneity 
exists in the adjudication criteria that were applied. Moreover, we had insufficient information to identify 
early recurrences that may have been due to thrombosis extension or to inadequate anticoagulation. 
Finally, we acknowledge the existence of studies conducted with other anticoagulant agents including 
danaparoid [40] and fondaparinux . However treatment with the heparinoid  is not standard of practice 
and is not listed in the recommended strategies in the most important guidelines [ACCP, RCOG],  in 
addition in our search we identified one study on the use of danaparoid in pregnant patients who were 
intolerant to heparin (also in case of previous HIT), but in this article we could not distinguish data from 
patients treated for an acute episode of VTE or for the prophylaxis of VTE,  so we decided to not include 
the study in the meta-analysis; whereas none of the studies with fondaparinux was eligible for inclusion in 
our study because none had more than 10 included patients. 
In conclusion, this is to our knowledge the first systematic review and meta-analysis specifically aimed to 
estimate the incidence of recurrent VTE and bleeding during anticoagulant treatment for pregnancy-
related VTE. The results of this study suggest that anticoagulant drugs during pregnancy are effective in 
the prevention of recurrent VTE, with an acceptable safety profile. Most events, both bleeding and 
recurrences, occurred during the first week of treatment. We could not identify the optimal therapeutic 
regimen among the different approaches used in the selected studies. 
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Table 1: Baseline characteristics of the study populations 
 
Author Patients 
(number) 
Age Gestational age BMI DVT  PE  
Aburahma1999 [19]  
 
24 
 
Mean 24 (17-39) y 1 first trimester 
5 second trimester 
18  third trimester 
nr 24 nr 
Bahlmann 2000 
[20] 
12 nr 26.1±6.2 nr 12 0 
Barillari 2007 [21] 38 nr nr nr nr nr 
Blanco-Molina 2010 
[22] 
 
173 mean 31±6 y 
 
nr nr 135 38 
Clark 2008 [23] 
 
17 nr median 19 w (7-
34w) 
 
nr nr nr 
Daskalakis 1997 
[24] 
 
18 27-43 y 7-38 w nr 18 0 
Donnelly 2012 [25] 25 nr nr nr 21 4 
Jacobsen 2003 [26] 20 mean 31.8±5.19 y 4 first trimester       
6 second trimester  
11third trimester 
 
nr 19 2 
Mitic 2011 [27] 87 mean 29.7±4.86 mean 22 w± 10.2w nr 82 5 
Narin 2008 [28] 35 
18 gruop I 
17 group II 
Mean 28.4±3.5 y 
group I 
 mean 30.0±5.2 y 
groupII 
 
mean 29.3 w 
±4.4w group I 
mean 26.5±6.5w 
group II 
 
nr 35 0 
Nelson-Piercy 2011 
[29] 
247 mean 30.1y* nr mean 
27.7* 
nr nr 
O’Connor 2010 [30] 34 nr nr nr nr nr 
Parent 2007 [31] 39 mean 32.5 y nr nr 20 19 
Rodie 2002 [32] 29 nr nr nr 23 6 
Roshani 2011[33] 13 Mean 32 nr nr 8 5 
Rowan 2003 [34] 13 nr nr nr nr nr 
Ulander 2002 [35] 31 
10 group I 
21 group II 
31.0±5.7  y  group 
I                
31.6 ±4.3 y group 
II 
 
27.±8.5 w group I                      
21 ±9.8 w group II 
 
23.4±4.7 
group I               
25. ±4.6 
group II 
 
31 0 
Voke 2007 [36] 126 median  32(16-42) 
y 
 
31 first trimester                 
37 second 
trimester             
58 third trimester 
 
median 
26 (19-
43) 
 
78 48 
Total    18 studies 981    506 127 
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BMI Body Mass Index, DVT deep vein thrombosis, PE Pulmonary Embolism, y years, w weeks, nr not 
reported 
*data regarding 252 patients treated with therapeutic tinzaparin 
 
Table 2: Treatment regimens for the acute phase of venous thromboembolism 
 
Author LMWH Dose of LMWH UFH Dose of UFH WARFARIN 
Aburahma 
1999 [19]  
 
0 - 24 11 pt i.v. according to 
aPTT (target 1.5-2.5 
times normal);  
13 pt i.v. bolus then 
5000-10000 U s.c. every 
8-12 hours 
0 
Bahlmann 
2000 [20] 
1 dalteparin 5000 IU s.c 3 
times day 
11 According to aPTT 
(target 1.5-2.0 times 
normal ) 
0 
Barillari 2007 
[21] 
38 nadroparin 100 IU/Kg bid 0 - 0 
Blanco-Molina* 
2010 [22] 
 
154 Mean 187±51 
IU/Kg/day 
16  Nr 0 
Clark 2008 [23] 
 
2 enoxaparin 100-110 mg/kg 
bid 
15 6 pt s.c. 0 
Daskalakis 
1997 [24] 
 
0 - 18 
 
According to aPTT 
(target 2.0 times normal) 
0 
Donnelly 2012 
[25] 
25 nr 0 - 0 
Jacobsen 2003 
[26] 
20 dalteparin initially 100 
IU/Kg bid then 
according to anti 
Xa levels (0.5-
1.0 U/ml) 
0 - 0 
Mitic 2011 [27] 84 
83 nadroparin 
1 dalteparin 
100IU/Kg bid 3 nr 0 
Narin 2008 [28] 0 - 35 According to aPTT 
(target 1.5-2.5 times 
normal ) 
0 
Nelson-Piercy 
2011 [29] 
247 tinzaparin median 13000 
IU (3500-
28000)† 
0 - 0 
O’Connor 2010 
[30] 
23 nr 11 nr 0 
Parent 2007 
[31] 
39 tinzaparin 18119 UI/Kg/day 0 - 0 
Rodie 2002 
[32] 
29 enoxaparin 1mg/Kg bid 0 - 0 
Roshani 
2011°[33] 
9 nadroparin 
2 dalteparin 
100IU/Kg bid or 
200IU/Kg od 
 
 
1 nr 0 
Rowan 2003 
[34] 
13 enoxaparin  1mg/Kg bid 0 - 0 
Ulander 2002 
[35] 
21 dalteparin  Based on anti 
Xa (target 1-1.5 
U/ml) 
10   According to aPTT (70-
100s) 
0 
Voke 2007 [36] 115 83 pt od 
39pt  bid 
11 nr 0 
Total 822 
 
 155  0 
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Table 3: Treatment regimens for the long term treatment period  
Author LMWH Dose UFH Dose WARFARIN Duration therapy 
Aburahma1999 
[19] 
 
0 - 24 5000-10000 U 
s.c. every 8-12 h 
0 6-8 weeks after 
delivery 
Bahlmann 2000 
[20] 
2  500-600 IU/h i.v. 10 
8 s.c. 
2 i.v. 
5000-7000 Ux3 
s.c. 
0 nr 
Barillari 2007 
[21] 
38  80-100IU/Kg once 0  0 3 months after 
delivery 
Blanco-Molina* 
2010 [22] 
 
133 Mean  173 ±59 
IU/Kg/day 
0 - 36 nr 
Clark 2008 [23] 
 
3 70 mg/Kd bid 
17000 IU od 
14 s.c. 9000-13000 IU 
every 8-12 h 
0 nr 
Daskalakis 1997 
[24] 
 
18  6150 anti Xa IU od  
 
0 - 0 1 month after delivery 
Donnelly 2012 
[25] 
25 nr 0 - 0 nr 
Jacobsen 2003 
[26] 
20  According to anti Xa 
levels (0.5-1.0 U/ml) 
0 - 0 nr 
Mitic 2011 [27] 85 Intermediate dosage 2 nr 0 nr 
Narin 2008 [28] 35  1 mg/Kg bid group I 
1.5 mg/Kg od group II 
0 - 0 nr 
Nelson-Piercy 
2011 [29] 
247 median 13000 IU 
(3500-23100)† 
0 - 0 nr 
O’Connor 2010 
[30] 
23 nr 11 nr nr nr 
Parent 2007 [31] 39 According to anti Xa 
levels 
0  0 2210 w 
Rodie 2002 [32] 29 According to anti Xa 
levels (0.4-1.0 U/ml) 
0 - 0 Median 6w (1-33w) 
Roshani 2011 
[33] 
9 nadroparin 
2 dalteparin 
100IU/Kg bid or 
200IU/Kg od 
 
 
1 nr 0 nr 
Rowan 2003 
[34] 
13 Some patients 
according to anti Xa 
levels 
0 - 0 nr 
Ulander 2002 
[35] 
31 100 UI/Kg bid for 2 
weeks then od 
according to anti Xa 
levels (0.7U/ml and 
0.5-0.6 at the end of 
pregnancy) 
0 - 0 nr 
Voke 2007 [36] 118 Some patient according 
to antiXa levels 
4 nr 0 nr 
Total 874  66  36  
LMWH low molecular weight heparin; UFH unfractionated heparin; IU International units; od once daily; 
bid bis in die; h hours; pt: patients; i.v: intravenous; s.c: subcoutaneous; nr: not reported; w weeks 
*data reported only for 169 patients 
† data regarding 252 patients treated with therapeutic tinzaparin 
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Table 4: Adverse events 
Author Ante-partum 
bleeding 
Ante-partum 
recurrent 
VTE 
Other antepartum 
adverse events 
Peri-partum 
bleeding 
(first 24 h 
after delivery) 
Other  
Post-
partum 
bleeding 
 
Other 
post 
partum 
adverse 
events 
FU 
Aburahma1999  
[19] 
 
1 retroperitoneal 
bleeding in acute 
phase*  
2 PE one fatal 
in acute 
phase*on UFH 
nr nr nr nr 61 
Months 
(18-102) 
Bahlmann 2000 
[20] 
nr 4 (2 PE): 3 in 
acute phase on 
UFH 
nr nr nr nr nr 
Barillari 2007 
[21] 
0 0 0 0 1 epystaxis nr 1 year 
after 
delivery  
Blanco-Molina 
2010  [22] 
 
3 major in acute 
phase*: 2 on UFH; 1 
on LMWH 
2 PE during 
LMWH after 
the acute 
phase* 
nr nr nr nr 3 
months 
after 
VTE 
Clark 2008 [23] 
 
0 1 PE in acute 
phase* on 
LMWH 
nr 1 wound 
hematoma, 1 
minor bleeding 
 
1 clinically 
relevant 
non major 
bleeding; 
1 major 
nr nr 
Daskalakis 1997 
[24] 
 
0 0 1 abortion (at 10°w) 0 nr 0 nr 
Donnelly 2012 
[25] 
nr nr nr 0  bleeding > 
1500 ml 
nr nr nr 
Jacobsen 2003 
[26] 
0 0 1 intrauterine death 
(at 37° w) 
1 atonic post 
partum 
bleeding, 1 
wound 
hematoma 
nr 0 nr 
Mitic 2011 [27] 3 minor 
 
1 DVT in acute 
phase* on 
LMWH 
4 skin reactions on 
nadroparin 
1 fetal loss (at 8°w) 
2  clinically 
relevant non 
major 
bleedings 
2 minor 
bleedings 
1 wound 
hematoma 
0 0 nr 
Narin 2008 [28] 1 vaginal bleeding 
1 hematuria , and 1 
clinically relevant 
vaginal on LMWH  
0 1 abortion (at 9 w) 0 0 0 4-8-w 
after 
delivery 
in 57% 
of pt 
Nelson-Piercy 
2012 [29] 
4‡ unspecified 5 (4 PE) ° nr 196 bleedings 
<500 ml 
31 bleedings 
>500 ml<1000 
3 bleeding s> 
1000 ml † 
nr 2 
stillbirths 
1 
terminatio
n § 
nr 
O’Connor 2010 
[30] 
2 unspecified nr nr Nr 4 
unspecified 
nr nr 
Parent 2007 [31] 1 hematuria 
2 vaginal bleeding 
1 major  on LMWH 
0 1 fetal death 
1 abortion 
1 eclampsia with 
thrombocytopenia  
(gestational age not 
specified) 
1 wound 
hematoma 
nr nr nr 
Rodie 2002 [32] 0 0 2 Skin reactions (on 
enoxaparin) 
3 atonic post-
partum 
bleeding,  
1 wound 
hematoma 
nr 0 nr 
Roshani 2011 
[33] 
0 0 nr 2 major 
bleedings 
2 bleedings 
<1000cc  
1 nr nr 
Rowan 2003 
[34] 
0 0 nr Nr nr nr nr 
Ulander 2002 
[35] 
1 hematuria  1 during 
LMWH after 
the acute 
phase* 
1 premature 
delivery (at 23° w) 
3 abnormal 
bleeding s> 
1000 ml;  
1 wound 
nr nr nr 
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hematoma  
Voke 2007 [36] 7 minor  0 2 intrauterine deaths 
(at 38° and 23° w), 
1 miscarriage (at 12 
w), 1  abortion (at 
12° w) 
6  bleedings> 
1000 ml;  
2 bleedings 
>500 ml<1000 
ml 
2 major 
bleeding; 4 
clinically 
relevant not 
major 
bleeding 
1 neonatal 
death 
nr 
Total 28: 
5 major 
1 clinically relevant 
non major 
16 minor 
6 unspecified 
16 °: 
11 PE; 1 fatal 
 
17: 
6 skin reactions 
4 abortion 
1 miscarriage 
4 intrauterine 
deaths 
1premature 
delivery 
1 eclampsia 
260: 
205 minor 
bleedings, 
41 clinically 
relevant non 
major 
bleedings, 
14 major 
bleedings 
14: 
3 major; 
5 clinically 
relevant; 
5unspecifie
d; 1 minor 
1 
neonatal 
death 
2 
stillbirths
§ 
1 
terminatio
n § 
 
VTE venous thromboembolism; FU follow-up; h hours; nr not reported; UFH unfractionated heparin; w 
weeks; pt patients 
* Acute phase: the first week after the diagnosis of TEV 
‡ data regarding 254 patients treated with therapeutic tinzaparin 
° in 2 cases recurrent VTE occurred after tinzaparin cessation 
† data regarding 229 patients treated with therapeutic tinzaparin 
§ data regarding 262 patients in therapeutic group 
 
 
 
 
Table 5: Bleeding complication rates 
 Incidence (%) 95% CI 
All ante-partum bleeding 
complications 
3.28 2.10-4.72 
Ante-partum major bleeding 1.41 0.60-2.41 
Acute ante-partum major 
bleeding* 
1.00 0.40-2.00 
Post-partum major bleeding (< 24 
hours) 
1.90 0.80-3.60 
Puerperium major bleeding† 1.2 0.30-2.5 
*Occurred during the first week after the introduction of anticoagulant therapy 
†Occurred after the first 24 hours after delivery 
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5019 selected references 
31 eligible in extenso 
studies+3 ISTH  eligible 
abstracts 
15 in extenso 
studies+3 ISTH 
abstracts 
4988 
references 
3 ISTH 
abstracts 
2 ASH 
abstracts 
6 excluded because 
data about DVT 
treatment were 
indistinguishable 
7 excluded because 
enrolled 10 or less 
patients 
2 excluded because no 
data about follow up 
1 excluded because 
no anticoagulant was 
used 
Figure 1: studies selection 
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References 
2180 
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2 ASH 
abstracts 
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abstracts 
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Figure 2  
All antepartum bleedings [WMD 3.28% (95% CI:2.10-4.72;I2 : 14.6%)] 
Proportion meta-analysis plot [random effects]
0,0 0,1 0,2 0,3
combined 0,0328 (0,0210, 0,0472)
Voke 2007 0,0556 (0,0226, 0,1111)
Ulander 2002 0,0323 (0,0008, 0,1670)
Rowan 2003 0,0000 (0,0000, 0,2471)
Roshani 2011 0,0000 (0,0000, 0,2471)
Rodie 2002 0,0000 (0,0000, 0,1194)
Parent 2007 0,1026 (0,0287, 0,2422)
O'Connor 2010 0,0588 (0,0072, 0,1968)
Nelson 0,0162 (0,0044, 0,0409)
Narin 2008 0,0857 (0,0180, 0,2306)
Mitic 2011 0,0345 (0,0072, 0,0975)
Jacobsen 2003 0,0000 (0,0000, 0,1684)
Daskalakis 1997 0,0000 (0,0000, 0,1853)
Clark 2008 0,0000 (0,0000, 0,1951)
Blanco-Molina 2010 0,0173 (0,0036, 0,0498)
Barillari 2007 0,0000 (0,0000, 0,0925)
Aburahma1999 0,0417 (0,0011, 0,2112)
proportion (95% confidence interval)
 
 
Major antepartum bleedings [WMD 1.41 % (95% CI:0.60-2.41;I2:0%] 
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Proportion meta-analysis plot [random effects]
0,0 0,1 0,2 0,3
combined 0,0141 (0,0068, 0,0241)
Voke 2007 0,0000 (0,0000, 0,0289)
Ulander 2002 0,0000 (0,0000, 0,1122)
Rowan 2003 0,0000 (0,0000, 0,2471)
Roshani 2011 0,0000 (0,0000, 0,2471)
Rodie 2002 0,0000 (0,0000, 0,1194)
Parent 2007 0,0256 (0,0006, 0,1348)
O'Connor 2010 0,0588 (0,0072, 0,1968)
Narin 2008 0,0286 (0,0007, 0,1492)
Mitic 2011 0,0000 (0,0000, 0,0415)
Jacobsen 2003 0,0000 (0,0000, 0,1684)
Daskalakis 1997 0,0000 (0,0000, 0,1853)
Clark 2008 0,0000 (0,0000, 0,1951)
Blanco-Molina 2010 0,0173 (0,0036, 0,0498)
Barillari 2007 0,0000 (0,0000, 0,0925)
Aburahma1999 0,0417 (0,0011, 0,2112)
proportion (95% confidence interval)
 
Major bleeding in the first 24 hours postpartum [WMD 1.00 % (95% CI:0.4-2.0%;I2:0%] 
Proportion meta-analysis plot [random effects]
0,0 0,2 0,4 0,6
combined 0,019 (0,008, 0,036)
Voke 2007 0,048 (0,018, 0,101)
Ulander 2002 0,097 (0,020, 0,258)
Roshani 2011 0,154 (0,019, 0,454)
Rodie 2002 0,000 (0,000, 0,119)
Parent 2007 0,000 (0,000, 0,090)
Nelson 2011 0,012 (0,003, 0,035)
Narin 2008 0,000 (0,000, 0,100)
Mitic 2011 0,000 (0,000, 0,042)
Jacobsen 2003 0,000 (0,000, 0,168)
Donnelly 2012 0,000 (0,000, 0,137)
Daskalakis 1997 0,000 (0,000, 0,185)
Clark 2008 0,000 (0,000, 0,195)
Barillari 2007 0,000 (0,000, 0,093)
proportion (95% confidence interval)
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Major post-partum bleedings after 24 hours è [WMD (1.2%, 95% CI:0.30-2.50%; I2:0%)]  
Proportion meta-analysis plot [random effects]
0,0 0,1 0,2 0,3
combined 0,012 (0,003, 0,025)
Voke 2007 0,016 (0,002, 0,056)
Roshani 2011 0,000 (0,000, 0,247)
O'Connor 2010 0,000 (0,000, 0,103)
Narin 2008 0,000 (0,000, 0,100)
Mitic 2011 0,000 (0,000, 0,042)
Clark 2008 0,059 (0,001, 0,287)
Barillari 2007 0,000 (0,000, 0,093)
proportion (95% confidence interval)
 
 
Figure 3: Ante-partum recurrent [VTE WMD 1.97% (95% CI:0.88-3.49% I2: 39.5%)] 
Proportion meta-analysis plot [random effects]
0,0 0,2 0,4 0,6 0,8
combined 0,0197 (0,0088, 0,0349)
Voke 2007 0,0000 (0,0000, 0,0289)
Ulander 2002 0,0323 (0,0008, 0,1670)
Rowan 2003 0,0000 (0,0000, 0,2471)
Roshani 2011 0,0000 (0,0000, 0,2471)
Rodie 2002 0,0000 (0,0000, 0,1194)
Parent 2007 0,0000 (0,0000, 0,0903)
Nelson 2011 0,0202 (0,0066, 0,0466)
Narin 2008 0,0000 (0,0000, 0,1000)
Mitic 2011 0,0115 (0,0003, 0,0624)
Jacobsen 2003 0,0000 (0,0000, 0,1684)
Daskalakis 1997 0,0000 (0,0000, 0,1853)
Clark 2008 0,0588 (0,0015, 0,2869)
Blanco-Molina 2010 0,0116 (0,0014, 0,0411)
Barillari 2007 0,0000 (0,0000, 0,0925)
Bahlmann 2000 0,3333 (0,0992, 0,6511)
Aburahma 1999 0,0833 (0,0103, 0,2700)
proportion (95% confidence interval)
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Terapia anticoagulante orale  
La terapia con inibitori della vitamina K (AVK) è indicata nella prevenzione primaria e 
secondaria di eventi trombotici arteriosi e venosi;  in particolare tali farmaci vengono 
utilizzati frequentemente nella prevenzione di embolie sistemiche in pazienti portatori di 
protesi valvolari cardiache o in pazienti affetti da fibrillazione atriale e nella terapia di 
eventi tromboembolici venosi.28 
La fibrillazione atriale è la più comune alterazione del ritmo cardiaco e rappresenta un 
importante fattore di rischio per lo sviluppo di ictus ischemico. La sua frequenza 
aumenta in modo proporzionale all’età, raggiungendo una prevalenza  del 10% circa 
nei soggetti con più di 80 anni29. E’ ormai noto che pazienti portatori di protesi valvolari 
meccaniche cardiache necessitino di un terapia anticoagulante a lungo termine30; infatti 
il rischio di complicanze emboliche o trombosi di valvola si attesta attorno al 12% e al 
22% all’anno rispettivamente in caso si tratti di una protesi tipo St. Jude in posizione 
aortica o mitralica31.  
Gli AVK sono stati per molto tempo l’unica terapia anticoagulante orale disponibile in 
commercio;  esercitano la loro azione anticoagulante interferendo con la conversione 
della vitamina K nel suo epossido, molecola fondamentale nel processo di 
carbossilazione di alcuni fattori della coagulazione (fattore II, VII, IX e X), definiti 
pertanto vitamina K dipendenti.  
 In tutto il mondo il AVK più utilizzato è rappresentato dal warfarin; questo presenta due 
forme enantiomeriche S- ed R-warfarin32. La forma S è un antagonista della vitamina K 
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chest physicians (9th edition). Chest 2012; 141(2)(Suppl):e44S–e88S 
29
  You JJ, Singer  DE, Howard PA  et al. Antithrombotic therapy  for atrial fibrillation: American 
college of chest physicians (9th edition). Chest 2012; 141(2)(Suppl):e531S–e575S 
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Valvular  Disease: American college of chest physicians (9th edition). Chest 2012; 141 (2) 
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3-5 volte più potente rispetto alla forma R33. Entrambi gli enantiomeri subiscono un 
forte metabolismo epatico prima dell’escrezione. Il CYP2C9 è il principale enzima 
responsabile della metabolizzazione dell’S-warfarin ciò rende gli SNPs (single 
nucleotide polymorphisms) in questo enzima particolarmente importanti nel 
determinare la variabilità della terapia con questo farmaco. Tra questi gli SNPs con una 
maggiore frequenza allelica nella popolazione caucasica sono il CYP2C9*2 
(rs1799853, R144C) e il CYP2C9*3 (rs4362691, I359L)  che portano alla formazione di 
un enzima con una ridotta capacità di idrossilare l’S-warfarin, diversi studi hanno 
mostrato come queste varianti alleliche portano alla necessità di modificare la dose del 
farmaco34. L’R-warfarin è metabolizzato dai citocromi appartenenti alle isoforme 
CYP1A2 e CYP3A, con una prevalenza della forma 3A35. L’attività enzimatica della 
famiglia di citocromi 3A è dovuta alle isoforme 3A4 e 3A5 che hanno la medesima 
specificità di substrato. Esiste una considerevole variabilità nell’attività enzimatica del 
CYP3A4 e diversi polimorfismi sono stati finora identificati per questo gene, tuttavia 
fino ad ora le basi molecolari alla base di tale variabilità non sono ancora state 
perfettamente comprese. Il CYP3A5 costituisce il 17-50% del CYP3A presente al livello 
epatico36. Per questo enzima è stata identificata una variante allelica detta CYP3A5*6 
che porta ad un difetto dello splicing con conseguente drastica riduzione dell’attività 
enzimatica. Per questo motivi il polimorfismo CYP3A4*5 rappresenta, nella 
popolazione caucasica la principale causa di variabilità per la famiglia del citocromo 
CYP3A. 
Anche la P-glicoproteina (p-GP) sembra contribuire alla variabilità nella risposta la 
warfarin. La P-GP appartiene alla classe delle proteine trasportatrici adenosine 
triphosphate-binding cassette (ABC), di cui costituisce l’isoforma B1, espressa in 
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 Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant 
response to warfarin. Pharmacogenomics J 2003; 3: 202–214 
34
 Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in 
anticoagulant response to warfarin. Pharmacogenomics J 2003; 3: 202–214 
35
 Kaminsky LS, Zhang Z. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67–
74 
36
 Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP 3A 
promoters and characterization of the genetic basis of polymorphic CYP 3A5 expression. Nat 
Genet 2001; 27: 383–391 
 55 
diversi tessuti come intestino, fegato, rene, barriera emato-encefalica e la placenta e 
che agisce come una pompa di efflusso per diverse molecole lipofiliche che sono 
frequentemente substrato del CYP3A37. Una volta assorbito, il  warfarin agisce a livello 
epatico, dove inibisce la vitamina K epossido reduttasi38. Almeno in teoria quindi una 
riduzione dell’attività della P-GP potrebbe portare ad un aumento dei livelli del farmaco 
a livello delle cellule bersaglio aumentando la sensibilità di alcuni pazienti per il 
warfarin. Finora sono stati identificati diversi polimorfismo per il gene ABCB1 (ad 
esempio: rs4362691, rs4362691, rs4362691), che sembrano essere importanti nel 
determinare variazioni nella biodisponibilità de farmaci substrato per questo 
trasportatore, anche se i risvolti farmacologici e clinici di questi SNPs non sono stati 
ancora completamente chiariti 39. 
Nei pazienti trattati con warfarin viene monitorato il tempo di protrombina (prothrombin 
time - PT) che viene espresso come rapporto internazionale normalizzato (international 
normalised ratio - INR), un indice che dà la misura della somma delle attività dei fattori 
di coagulazione dipendenti dalla vitamina K II, VII e X. Le variazioni interindividuali 
nella risposta la warfarin e il basso indice terapeutico sono due tra i principali fattori che 
rendono difficoltosa la terapia con questo farmaco. Il sesso, l’età, malattie epatiche 
(che riducono la sintesi dei fattori di coagulazione), stati ipermetabolici (che aumentano 
la clearance dei fattori di coagulazione), insufficienza cardiaca (che altera la 
distribuzione del warfarin) sono tutti fattori in grado di ridurre la sensibilità per il 
farmaco che quindi richiedono la riduzione del dosaggio40. Al contrario l’eccessivo 
                                                 
37
 Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and 
cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999; 59: 
3944–3948 
38
 Linder MW. Gentic mechanisms for hypersensitivity and resistance to the anticoagulant 
warfarin. Clin Chim Acta 2001; 308: 9–15 
39
 Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmo¨ller J, Johne A et al. Functional 
polymorphisms of the human multidrug-resistance gene: multiple sequence variations and 
correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci 
USA 2000; 97: 3473–3478 
40
 Penning van Beest FJA, van Meegen E, Rosendaal FR, Stricker BHC. Characteristics of 
anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001; 
86: 569–574 
 56 
introito alimentare di vitamina K potrebbe richiedere un aumento del dosaggio del 
farmaco.  
Inoltre studi clinici hanno dimostrato che  in centri specializzati la stabilità di valori di 
INR, espressa come percentuale di tempo in range terapeutico, si attesta in media 
attorno al 60% e che esistono fattori associati ad una maggiore stabilità dei valori di 
INR come ad esempio l'assenza di scompenso cardiaco o di diabete41.  
Esiste la possibilità che vi sia anche una predisposizione genetica alla risposta al 
warfarin che potrebbe influenzare la stabilità del trattamento, tuttavia nessuno studio 
ha fino ad ora valutato questo effetto sulla stabilità a lungo termine. 
Il warfarin è stato oggetto di numerosi studi compiuti allo scopo di identificare i fattori 
alla base dell’ampia variabilità interindividuale nel dosaggio a questo farmaco, ma solo 
per quanto riguarda il fabbisogno iniziale relativo alle prime settimane di terapia. Da 
questi studi sono emersi diversi algoritmi sia comprendenti variabili genetiche che non 
genetiche allo scopo di stabilire un dosaggio ottimale per il warfarin in ogni paziente42.  
Gli SNPs nei geni di VKORC1 e CYP2C9 sono tra le variabili più informative in diversi 
algoritmi  utilizzati per definire il dosaggio del warfarin.  
Tali evidenze comunque non escludono la possibilità che SNPs in altri geni possano 
contribuire alle differenze interindividuali nel dosaggio del warfarin anche a lungo 
termine.  
E’ stato quindi condotto uno  studio volto ad identificare i fattori genetici che possono 
essere associati ad una maggiore o minore stabilità del warfarin nella fase cronica del 
trattamento, definita come il periodo successivo al primo mese di terapia. In particolare 
obiettivo dello studio è quello di stabilire se esiste un'associazione tra un particolare 
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SNP e/o una combinazione di differenti SNPs con la stabilità dei valori di INR, definita 
come tempo trascorso in range terapeutico (TTR)43. 
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ASSOCIATION BETWEEN ABCG2 AND ABCB1 GENES AND WARFARIN STABILITY: 
A CASE-CONTROL STUDY44 
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Warfarin is the most prescribed oral anticoagulant worldwide and is largely used for the primary and 
secondary prevention of thromboembolic events[1]. The management of warfarin therapy is complex and 
requires a regular monitoring of the international normalized ratio (INR)[2]. Even in specialized centers, 
only about 60% of INR values are within the therapeutic range, with a consequent increased risk of 
developing thrombotic or haemorrhagic complications[3]. Several variables have been associated with 
INR stability, in particular age, sex, hepatic disorders, cardiac failure, concomitant drugs and low intake 
of vitamin K[2,4], however several authors suggest that genetic variant in both pharmacokinetic that 
pharmacodynamic genes play a key role in warfarin response. 
Warfarin is predominantly metabolized by cytochrome P-450 (CYP) 2C9[5] and produces 
pharmacodynamic effects by inhibiting vitamin K epoxide reductase complex subunit 1 (VKORC1). 
Several pharmacogenetic studies have previously shown that polymorphic alleles within CYP2C9 and 
VKORC1 genes are related to warfarin dose requirement[6], conversely, only few data are available on the 
association between gene polymorphisms and warfarin stability. Warfarin pharmacokinetic is influenced 
also by intestinal transporter such as P-glycoprotein (P-GP) coding by ABCB1 genes[7], a potent efflux 
pump for a wide variety of lipophilic compounds[8,9]. P-GP have a large substrates overlapping with 
Breast Cancer Resistance Protein (BCRP), other intestine transporters, coding by ABCG2 gene. 
Individuals carrying SNPs in both ABCB1 and ABCG2 have low levels of protein expression[10], that, at 
least for ABCB1, resulting in increased bioavailability and higher plasma warfarin concentrations[11]. So 
far, BCRP (coded by ABCG2) role in warfarin disposition has never been investigated; however a 
contribution may be well hypothesized, considering the large overlapping of substrates with P-
glycoprotein[12-15]. 
The aim of our study was to assess whether genetic polymorphisms in important genes for warfarin 
pharmacokinetic and pharmacodynamic such as ABCB1, ABCG2, CYP2C9, and VKORC1 are 
associated with warfarin stability in patients on long-term therapy. 
 
Methods. 
From November 2010 to November 2011, all patients on long term warfarin therapy for atrial fibrillations 
(AF) or presence of mechanical heart valves (MHV) and with unstable warfarin therapy followed at the 
Anticoagulation Clinic of the Ospedale di Circolo, Varese, Italy were enrolled. Patients with stable 
warfarin therapy and matched for: age, sex, warfarin dose, indication and duration of anticoagulant 
therapy, concomitant drugs, alcohol use, smoking habit, weighted index of comorbidity (WIC)[16] and the 
mean vitamin K intake with diet, were enrolled as controls. 
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Warfarin stability was measured as the time spent in therapeutic range (TTR), estimated by linear 
interpolation between successive INR measurements, using methods published by Rosendaal[17]. In a 6-
month period a TTR ≤55% defined unstable patients and a TTR ≥85% defined stable patients. Exclusion 
criteria were: patients on warfarin for less than 6 month; temporary stop of anticoagulant therapy during 
the 6-month period; renal (Glomerular Filtration Rate ≤ 90 mL/min/1.73 m2) or hepatic (transaminases 
elevation upper normal limit) failure and inadequate compliance in following medical prescriptions on 
anticoagulant treatment[18]. The following information was collected for all patients: age, sex, TTR, 
warfarin dose at the time of enrolment, indication and duration of anticoagulant therapy, concomitant 
drugs, alcohol use, smoking habit, weighted index of comorbidity[19] and the mean vitamin K intake with 
diet by a food frequency questionnaire[20]. The Institutional Review Board approved the study, and all 
eligible patients provided written informed consent. 
Genotyping was performed by Real Time PCR on an Applied Biosystems GeneAmp 9700 PCR System 
(ABI, Foster City, California) using a pre-designed genotyping assay (Applied Biosystems, Foster City, 
California, USA). The candidate gene polymorphisms are listed in Table 1. 
Continuous variables are expressed as mean±standard deviation (SD); categorical data are given as counts 
and percentages. Each polymorphism was tested to ensure that it fitted Hardy–Weinberg equilibrium. The 
associations between categorical variables were assessed by Fisher’s exact test. The odds ratios (OR) with 
the corresponding 95% confidence interval (CI) were calculated. 
To explore the potential effects of interactions between genes, we identified SNPs combinations by a 
logistic additive model. Frequencies of different SNPs combinations were estimated using the 
implementation of the EM algorithm coded into the aplo.stats package[21]. The most frequent SNPs 
combinations was selected as the references category and rare SNPs combinations (frequency <3%) were 
pooled together in a group. Association between SNPs combinations and TTR were accomplished using 
Fisher’s exact test. 
 
 
 
 
Table 1. SNPs considered in the study. 
Gene Full name SNPs Genotype SNPs effects 
ABCB1  ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
rs1128503 C1236T Reduced gene expression [10] 
 
 rs1045642 C3425T Reduced gene expression [10] 
ABCG2  ATP-binding cassette, sub-family G 
(breast cancer resistance protein), 
member 2 
rs2231142 C421A Reduced transport function 
and drug efflux [10] 
CYP2C9 Cytocrome P450, family 2, 
subfamily C, member 9 
rs1057910 A1075C Reduced catalytic activity [6] 
 
 rs1799853 C8633T Reduced catalytic activity [6] 
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CYP3A5 Cytocrome P450, family 3, 
subfamily a, member 5 
rs776746 G6986A Reduced catalytic activity [28] 
 
    
VKORC1  
 
Vitamin K epoxide reductase 
complex subunit 1 
rs7294 G3673A Increased gene expression [27] 
 
 rs9934438 C6484T Reduced gene expression [6] 
 
Results. 
Patients and controls had similar age, gender distribution and indication for anticoagulation. BMI, 
warfarin weekly dose and weighted comorbidity index were also similar between the two groups (Table 
2). The mean value of TTR was 47.5±6.1% in cases and 93.7±5.3% in controls. Cases were on warfarin 
for a mean of 88 months, controls for a mean of 68 months.  There was no association between SNPs 
(genotype and combinations) and age, gender, BMI, treatment durations, warfarin dose or numbers of 
concomitant drugs. 
ABCG2 421C/A genotype was significantly more prevalent in unstable patients than in controls (36,4% 
vs 9,1%, p<0.016 resulting in a corresponding odds ratio of 5.7 (95% CI 1.4-22.8). No association was 
found between TTR and SNPs in both CYP that VKORC1 genes (Table 3). 
Using a logistic additive model, we identified 4 SNPs combinations for SNPs in ABCB1 and ABCG2 
genes (named from 1 to 4), 4 SNPs combinations for SNPs in CYP3A5 and CYP2C9 (named from 5 to 
8), and 4 for SNPs in VKORC1 (named from 9 to 12) with a frequency greater than 3% (Table 4). SNPs 
combinations 3 (TTA) was only present in unstable patients, resulting in an OR of 30,7 (95% CI 2.3-53.0) 
(P<0.001) for a low TTR.  
No association was found between TTR and all other SNPs combinations (Table 4). 
 
Table 2. Characteristics of the subjects included in the study. Values are means ± DS. M, male; F, 
female; BMI, body max index; a.f., atrial fibrillations; hvp., heart valve prosthesis. 
 Total TTR>85% TTR<55% 
number 66 33 33 
age (years) 76.8±6.6 76.6±6.5 75.6±6.7 
gender M/F 34/32 17/16 17/16 
BMI 26.4±4.1 26.3±4.0 26.5±4.3 
Disease (af/hvp) 54/12 27/6 27/6 
Warfarin dose (mg/sett) 25.2±11.2 24.1±10.4 26.3±13 
TTR (%) 70.7±23.9 47.54±6.1 93.66±5.3 
Concomitant drugs 4.8±2.5 4.48±2.4 5.15±2.6 
Mean of weighted index of comorbidity 0.87 0.85 0.91 
 61 
Table 3. SNPs Frequency and correlations with warfarin stability. 
Gene SNP Genotype TTR >85% TTR <55% OR (95% CI) P-value 
ABCB1 rs1128503 C/C 9 (27.3%) 3 (9.1%) 3.1 (0.9-11.7) 0.130 
 
 
C/T 20 (60.6%) 20 (60.6%) 
 
 
 
 
T/T 4 (12.1%) 10 (30.3%) 
 
 
 
     
 ABCB1 rs1045642 C/C 8 (24.2%) 3 (9.1%) 3.1 (0.9-11.7) 0.130 
 
 
C/T 21 (63.6%) 20 (60.6%) 
  
 
 
T/T 4 (12.1%) 10 (30.3%) 
  
 
 ABCG2 rs2231142 C/C 30 (90.9%) 21 (63.6%) 5.7 (1.4-22.8) <0.016 
 
 
C/A 3 (9.1%) 12 (36.4%) 
  
  
C/C 0 (0%) 0 (0%) 
  
 
      CYP2C9 rs1799853 C/C 19 (57.6%) 26 (78.8%) 0.4 (0.1-1.1) 0.111 
 
 
C/T 14 (42.4%) 7 (21.2%) 
  
 
 T/T 0 (0%) 0 (0%)   
 
      
CTP2C9 rs1057910 A/A 26 (78.8%) 28 (84.8%) 0.7 (0.2-2.3) 0.751 
 
 
A/C 7 (21.2%) 5 (15.2%) 
  
 
 C/C 0 (0%) 0 (0%)   
 
      
CYP3A5 rs776746 G/G 28 (84.8%) 27 (81.8%) 0.3 (0.01-8.8) 1.000 
 
 
A/G 4 (12.1%) 6 (18.2%) 
  
 
 
A/A 1 (3.0%) 0 (0.0%) 
  
 
      VKORC1 rs7294 G/G 11 (33.3%) 11 (33.3%) 0.4 (0.06-2.0) 0.426 
 
 
G/A 17 (51.5%) 20 (60.6%) 
  
 
 
A/A 5 (15.2%) 2 (6.1%) 
  
 
 VKORC1 rs9934438 C/C 6 (18.2%) 4 (12.1%) 1.8 (0.5-6.2) 0.532 
 
 
C/T 22 (66.7%) 21 (63.6%) 
  
 
 
T/T 5 (15.2%) 8 (24.2%) 
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Table 4. SNPs combinations frequencies for gene coding for warfarin transport (panel A), metabolism 
(panel B) and target (Panel C) and correlations with range TTR. 
Panel B 
 
CYP2C9 
C430T 
CYP2C9 
A1075C 
CYP3A5 
A6986G 
Total 
TTR 
>85% 
TTR 
<55% 
O.R. (95% 
CI) 
P 
1 C A G 0,65 0,61 0,74 1.00 - 
2 T A G 0,16 0,19 0,10 
0.4 (0.12-
1.3) 0.133 
3 C A A 0,09 0,09 0,08 
0.9 (0.27-
3.1) 0.882 
4 C C G 0,09 0,09 0,07 
0.7 (0.16-
2.8) 0.591 
rare * * * 0,01 0,02 0,00 1.0 (0.1-3.6) 0.698 
Panel C 
 
VKORC1 
G3673A 
VKORC1 
C7484T  
Total 
TTR 
>85% 
TTR 
<55% 
O.R. (95% 
CI) 
P 
1 G T 0,41 0,30 0,42 1.00  - 
2 A C 0,27 0,22 0,30 0.6 (0.2-1.8) 0.382 
3 G C 0,21 0,29 0,20 0.5 (0.2-1.0) 0.066 
4 A T 0,12 0,15 0,09 0.4 (0.2-1.1) 0.315 
 
Discussion. 
The main finding of our study is the association between ABCG2 C421A SNP and warfarin stability. To 
our best knowledge this is the first report of a significant association between warfarin stability and 
individual genotype.  
Several studies reported that genetic variants may contribute to the variability in warfarin response, and 
algorithms containing CYP2C9 and VKORC1 polymorphisms have been developed for estimating 
warfarin loading doses[5,22]. Conversely, only few data are available on the association between gene 
polymorphisms and warfarin stability, and recent studies, concluding that no association existed between 
the CYP2C9 and VKORC1 genotypes and therapy stability[5,23]. These results are consistent with our 
Panel A 
 
ABCB1 
C1236T 
ABCB1 
C3435T 
ABCG2 
C421A 
Total 
TTR 
>85% 
TTR 
<55% 
O.R. (95% 
CI) P 
1 C C C 0,43 0,50 0,34 1.00 - 
2 T T C 0,42 0,41 0,45 2.1 (0.7-6.8) 0.200 
3 T T A 0,08 0,00 0,13 
30.7 (2.3-
53.0) <0.001 
4 C T C 0,03 0,03 0,04 
2.0 (0.2-
26.3) 0.521 
rare * * * 0,05 0,06 0,04 
2.6 (0.2-
27.0) 0.492 
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study, which confirms that CYP2C9 and VKORC1 variants are not associated with warfarin stability 
(Table 3). However, we also explored the role of common and well characterized SNPs in ABCB1 and 
ABCG2 genes[24], which are relatively less studied genes implicated in warfarin pharmacokinetics. 
The most intriguing finding of our study was the significantly higher frequency of ABCG2 421A variant 
allele in subjects with low TTR as compared to stable patients (Table 3). The ABCG2 gene encodes an 
efflux pump, and the presence of the SNP C421A reduces the activity of this transporter. Impairment of 
warfarin transport could affect the warfarin stability in different ways. One hypothesis is that the 
worsening of the carrier activity increases the risk of interaction with other substrates with affinity for the 
pump. On the other hand in vitro BCRP is able to carry vitamin K[15], thus a second hypothesis is that 
reduced efficiency of the pump leads to changes in the vitamin K disposition, in turn affecting warfarin 
TTR[2,4]. 
It is widely accepted that complex gene-gene interactions exist and that the role of genetic differences in 
drug response are usually multifactorial, involving the contribution of multiple genes and gene variants. 
We therefore decided to explore the potential effects of gene-to-gene interactions. Using a logistic 
additive model, we identified SNPs combinations for studied SNPs (Table 2). We identified a significant 
association between low TTR and the TTA SNPs combinations formed by SNPs in genes coding for 
warfarin transport (namely ABCB1 and ABCG2). On the contrary, the SNPs combinations formed by 
SNPs in CYP2C9 and VKORC1 were not associated with TTR. The TTA SNPs combinations contains 
ABCB1 3435T, 1236T and ABCG2 421A alleles, all associated with impairment of warfarin transport 
activity thus supporting our hypothesis that reduction in warfarin efflux result in reduced TTR due to 
increases potential for interaction with other transporter substrates and/or alterations in vitamin K intake. 
The main limitation of our study is the small number of patients that does not allow to assess the 
prevalence of SNPs in anticoagulated patients. Moreover, we cannot exclude that additional genetic 
mutations not assessed in our study could also interfere with warfarin stability. The small sample size 
might also impact on the results of the statistical analysis, possibly leading to effects just due to chance. 
Nonetheless, in our opinion this is unlikely since the association between the ABCG2 gene SNP C421A 
is biologically plausible (as discussed above) and it has been confirmed by different approaches in data 
analysis, namely conventional comparison of genotypes (Table 3, P = 0.016) and SNP combination 
frequencies (Table 4, P<0.001); in particular, the level of significance of the latter result is well beyond 
the conventional 0.05 threshold for significance. Another limitation is the possible confounders in our 
study, indeed it is well-known that several patient characteristics influence warfarin stability[3,25]. To 
minimize this risk we matched cases and controls, our results shown that the distribution of major risk 
factors for warfarin instability was well balanced between the two groups thus reducing the risk 
confounders.  
In conclusion, the present study suggests that patient’s carriers of SNP in warfarin transporter protein 
alone or in combination may be at higher risk of unstable anticoagulant therapy. The results are only 
hypothesis-generating, and the association between the ABCG2 gene SNP C421A and stability of the 
response to warfarin must be confirmed into an appropriate prospective longitudinal study. Nonetheless, 
they may have a relevant clinical impact since patients with low TTR are at increased risk of developing 
thrombotic or hemorrhagic complications[2] and it could be important if individuals with a genetic 
predisposition to an unstable response to warfarin could be identified before starting therapy. These 
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patients could be either monitored more closely or could beneficiate from alternative anticoagulant 
therapies, such as the oral direct inhibitors[2,26]. 
 
References. 
1. Wang L, McLeod H, Weinshilboum RH. Genomics and drug response. N Engl J Med 2011; 
364:1144-53 
2. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral Anticoagulant 
Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest 
Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:e44S-88S. 
3. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM; 
Warfarin Associated Research Projects and other EnDeavors (WARPED) Consortium. Outcomes 
and predictors of very stable INR control during chronic anticoagulation therapy. Blood 
2009;114:952-6 
4. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J,Harats D, 
Halkin H, Ezra D.Interindividual variability in sensitivity to warfarin—nature or nurture? Clin 
Pharmacol Ther 2001; 70: 159–164 
5. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF,May HT, 
Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators. Randomized trial of 
genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. 
Circulation 2007;116:2563-70 
6. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly 
AK, Kamali F.The impact of CYP2C9 and VKORC1 genetic polymorphism and patient 
characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 
106:2329–2333. 
7. Sussman NL, Waltershied M, Butler T, Cali JJ, Riss T, Kelly JH. The predictive nature of high 
throughput toxicity screening using a human hepatocyte cell line. Cell Notes 2002; 3: 7–10, 
http://www.promega.-com/cnotes/cn003/cn003_07.htm. 
8. Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. 
Pharmacogenomics J 2001; 1: 59–64.  
9. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and 
cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999; 59: 3944–
3948.  
10. Wang D, Sadée W. Searching for polymorphisms that affect gene expression and mRNA 
processing: example ABCB1 (MDR1). AAPS J. 2006; 8:E515-20. 
11. De Oliveira Almeida VC, De Souza Ferreira AC, Ribeiro DD, Gomes Borges KB, Salles Moura 
Fernandes AP, Brunialti Godard AL. Association of the C3435T polymorphism of the MDR1 gene 
and therapeutic doses of warfarin in thrombophilic  patients. J Thromb Haemost. 2011; 9:2120-2  
12. Cramer J, Kopp S, Bates SE, Chiba P, Ecker GF. Multispecificity of drug transporters: probing 
inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2. ChemMedChem. 
2007; 2:1783-8. 
13. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, 
MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005; 204:216-37. 
 65 
14. Ejendal KF, Hrycyna CA. Differential sensitivities of the human ATP-binding cassette transporters 
ABCG2 and P-glycoprotein to cyclosporin A. Mol Pharmacol. 2005 Mar;67(3):902-11.  
15. Vlaming ML, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 (BCRP): 
recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev. 2009; 61:14-25. 
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-383 
17. Rosendaal FR, Cannegieter SC, van der Meer FJ. Briët E. A method to determine the optimal 
intensity of oral antico- agulant therapy. Thromb Haemost 1993;69:236–9 
18. Folstein MF, Folstein SE, McHugh PR "Mini-mental state". A practical method for grading the 
cognitive state of patients for the clinician. Journal of psychiatric research 1975; 12: 189–98 
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-383 
20. Couris RR, Tataronis GR, Booth SL, Dallal GE, Blumberg JB, Dwyer JT. Development of a self-
assessment instrument to determine daily intake and variability of dietary vitamin K. J Am Coll 
Nutr. 2000;19:801-807  
21. Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association 
studies. Bioinformatics. 2006; 22:1928-9. 
22. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al. 
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during 
warfarin therapy. JAMA 2002; 287: 1690–1698 
23. van Schie R. M. F., Babajeff, T. Schalekamp, J. A. M. Wessels, S. le Cessie, A. de Boer, F. J. M. 
van der Meer, E. van Meegen, T. I. Verhoef, F. R. Rosendaal and A. H. Maitland- van der Zee, for 
the EU-PACT study group.  An evaluation of gene-gene interaction between the CYP2C9 and 
VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. J 
Thromb Haemost. 2012; 10:767-72 
24. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and 
breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet. 2012; 27:85-105. 
25. Witt DM, Delate T, Clark NP, et al; Warped Consortium .Twelve-month outcomes and predictors of 
very stable INR control in prevalent warfarin users. J Thromb Haemost. 2010; 8: 744 - 749. 
26. Schurgers LJ, Shearer MJ, Hamulyák K, Stöcklin E, Vermeer C. Effect of vitamin K intake on the 
stability of oral anticoagulant treatment: dose-response relationshipsin healthy subjects. Blood. 
2004; 104: 2682 - 2689. 
27. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, 
Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual 
variability in the dose-anticoagulant effect of warfarin. Blood.2005; 105:645-9.  
28. Kuehl P1, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall 
SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski 
MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of 
polymorphic CYP3A5 expression. Nat Genet. 2001 Apr;27(4):383-91. 
 
 
 66 
 
CONCLUSIONI 
In questo progetto di dottorato si è cercato di studiare alcune condizioni inusuali che 
possono essere associate alla sviluppo di eventi cardiovascolari.  
Valutando pazienti affetti da trait talassemico abbiamo potuto concludere che questa 
condizione risulta essere protettiva, a differenza di quello che è stato segnalato per le 
forme di talassemia intermedia.  
Occupandoci di tireotossicosi abbiamo evidenziato come sia presente uno stato di 
ipercoagulabilità mediato dall’azione degli ormoni tiroidei, allo stato attuale non è 
ancora possibile definire quanto clinicamente questa condizioni si associ allo sviluppo 
di eventi trombotici; sarebbero  quindi necessari studi mirati anche per definire 
l’eventuale necessità di terapia profilattica antitrombotica da attuare in corso di 
ipertiroidismo. 
 Ci siamo quindi occupati della gravidanza,  una condizioni associata ad un aumentato 
rischio trombotico, in cui  non era ben chiaro quale fosse la terapia anticoagulante 
migliore. Siamo riusciti a radunare una casistica ragguardevole, dimostrando che 
l’eparina a basso peso molecolare è efficace,  è associata ad un rischio trombotico ed 
emorragico sovrapponibile a quello che si verifica in pazienti non gravide e soprattutto 
non è correlata a rischi evidenti per il feto. 
Nell’ultima parte della trattazione ci siamo soffermati sulla ricerca di alcuni fattori che 
potessero giustificare la presenza di una grave instabilità della terapia anticoagulante 
con AVK in particolari soggetti. Abbiamo individuato come la presenza di alcuni SNPs 
sia un indice predittivo di tale condizione. Questo fa sì che si possano individuare 
persone che, a causa del loro patrimonio genetico, non possano beneficiare di una 
terapia anticoagulante condotta con AVK, ma al contrario dovrebbero essere sottoposti 
ad una altro tipo di terapia come ad esempio ad una terapia con i nuovi anticoagulanti 
orali ( inibitori diretti del fattore X e II della coagulazione). Questi  nuovi farmaci 
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presentando un profilo farmacocinetico e farmacodinamico più regolare potrebbero 
garantire una maggiore stabilità della coagulazione, tuttavia sarebbero utili studi sugli 
effetti dei SNPs anche su questi. 
 
